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This study highlights the molecular mechanism of the anti-cancer activity of a 
lanthanide rare metal conjugate, praseodymium-mercaptopyridine oxide (Pr-MPO).  
This small molecule compound elicited potent activity against a variety of human 
cancer cell lines, including cancer cells rendered resistant to apoptotic execution, as 
well as significantly inhibited tumor growth in an in vivo murine xenograft model.  
Whereby, an impressive inhibition of tumor colony formation was observed at low 
micro molar concentrations, biochemical analyses as well as the use of pathway 
inhibitors revealed that the mode of cell death was non-apoptotic.  Interestingly, the 
compound robustly activated mTOR dependent autophagy; however, pharmacological 
and genetic inhibition of autophagy did not rescue cells, indicating that autophagy did 
not account for its anti-cancer activity.  Investigations into the molecular mechanisms 
underlying the anti-cancer activity revealed that the compound elicited its effect in a 
calcium dependent manner.  Chelating extracellular calcium completely abrogated the 
inhibition of tumor colony formation and rescued cells from Pr-MPO induced 
execution.  A closer look at the calcium dynamics using a variety of imaging 
techniques, such as real time confocal microscopy, showed a rapid increase in 
intracellular calcium in cells upon exposure to the compound.  This increase was 
distinctly different from the classical ER dependent increase upon treatment with 
thapsigargin. Using specific inhibitors, the involvement of ER dependent calcium 
signaling was ruled out in this model.  Furthermore, while the mitochondria was also 
not involved as a potential player in this calcium mediated cytotoxicity, real time 
imaging provided a punctate pattern of calcium accumulation within minutes of 




acidic vacuoles consistent with lysosomal structures.  Indeed, these organelles were 
verified as lysosomes by confocal microscopy, which also showed that chelating 
calcium completely inhibited puncta formation.  Furthermore, a direct relationship of 
intra-lysosomal proton concentration (acidic pH) and calcium accumulation was 
obtained, indicating that the compound triggered accumulation and/or retention of 
calcium in the lysosomes in a pH dependent manner; increase in lysosomal pH 
inhibited calcium puncta formation. Of note, chemical inhibition of lysosomal 
acidification not only blocked calcium accumulation in the lysosomes but also 
rescued cells from drug-induced cell death.  The involvement of lysosomes was 
further corroborated by the detection of increased cathepsin activity in cell lysates 
following drug treatment.  These results are the first report implicating lysosomal 
calcium as a mechanism of anti-cancer activity of a novel small molecule.  These 
interesting results could provide the backdrop for identifying specific calcium 
channels within the lysosomes responsible for calcium accumulation and/or retention 
as not much is known regarding these lysosomal transport systems in mammalian 
cells.   Taken together, this thesis contributes significantly to the understanding of the 
signaling triggered by a novel anti-cancer agent that targets cancer cells including 
those refractory to classical apoptosis inducers, and provides a new avenue for the 
design of strategic therapeutics by implicating a hitherto undefined lysosomal-calcium 
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1. Management of cancer 
1.1 Cancer  
Cancer is a disease of dysregulated and inappropriate growth of cells, which is 
brought about by a number of factors that collectively alter the balance between 
cellular processes that dictate cell proliferation and those responsible for death 
execution. In this respect, work over the last three to four decades has identified 
specific genes whose gain-of-function pushes cells towards transformation and others 
where loss of function results in the inability of the cells to control unwanted 
proliferation and growth. In another words, oncogenic mutations, such as activating 
mutations of Ras, Myc, AKT drive the process of carcinogenesis, which is kept in 
check by the tumor suppressor proteins like p53, BRCA1, Rb, etc. The carcinogenic 
activity of activated oncogenes is a result of constitutive activation of receptor 
signaling, decrease dependence on growth factor for survival, accumulation of DNA 
lesions; whereas the tumor suppressor functions rely on the ability of the proteins to 
induce cell cycle arrest, ensure quality control of DNA and DNA repair machinery, 
and more importantly trigger cell death in cells where the DNA damage is irreparable 
(Yokota 2000, Sherr 2004, Croce 2008). As a consequence of the altered balance 
between oncogenes and tumor suppressor genes, the cells acquire a variety of 
hallmarks that drive them to a cancerous phenotype (Hanahan and Weinberg 2000, 
Hanahan and Weinberg 2011). Therefore, the recent interest in targeting the 
transformed and/or cancer cells is heavily reliant on designing specific strategies to 




1.2 Conventional treatment of cancer 
The therapeutic management of cancer includes three major modalities, (i) surgical 
debulking; (ii) γ-radiation; and (iii) chemotherapy (Mieog, van der Hage et al. 2007, 
Sudhakar 2009). Whereas surgery and radiation therapy are pretty much limited for 
solid tumors, chemotherapy remains as a corner stone of drug treatment of all cancers. 
The earlier generation of chemotherapeutic drugs were designed to only select for 
cells with a higher proliferative capacity, such as the alkylating agents, DNA damage 
inducers, selective enzyme inhibitors, and anti-nucleoside transporters (Belanich, 
Pastor et al. 1996). These agents have served efficiently over many decades, however, 
their efficacy has been limited due to the selective emphasis on inhibiting proliferative 
networks. Since the realization that defective cell death signaling is an invariable 
finding in most clinical tumors, in addition to the constitutive activation of 
proliferative pathways, a more recent trend has been to design drugs that directly or 
indirectly target cell death pathways such as pro-apoptotic agents. Examples of this 
include small molecule compounds that selectively target mitochondrial death 
signaling pathways, DNA damaging agents that activate tumor suppressor induced 
cell cycle arrest and apoptosis as well as ligands of the death receptors (Debatin, 
Poncet et al. 2002). Moreover, as more and more evidence accumulated to link 
resistance to apoptosis as an acquired attribute of cancers, a second line of approach 
has been to develop chemical inhibitors of proteins that bestow upon cells the ability 
to blunt apoptotic signaling, such as inhibitors of Bcl-2, inhibitors of IAPs, and Smac 
mimetics (Hann, Daniel et al. 2008, Kang and Reynolds 2009, Awasthi, Kirane et al. 
2011, de Almagro and Vucic 2012). However, given the high incidence of resistance 
to apoptosis in cancers, these approaches have had limited success in the clinical 
setting, which suggests the existence of other hitherto undefined mechanisms of 
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apoptosis resistance. These facts strongly argue in favour of engaging other modes of 
cell death in order to increase the efficacy of cancer treatment, such as the emerging 
programmed necrotic cell death.   
 
2. Modes of Cell death 
2.1 Apoptosis 
Electron microscopic morphology of this mode of cell death was unraveled as early as 
a century ago. In 1972, Kerr, Wyllie and Currie initially christianed this cell demise 
with the term “apoptosis” in order to discriminate a naturally occurring developmental 
cell death from an uncontrolled, random accidental cell death that resulted in tissue 
inflammatory response (Kerr, Wyllie et al. 1972). Apoptosis, also called cellular 
suicide, is a genetically regulated and programmed process of cellular self-destruction; 
it plays a pivotal role in maintaining tissue homeostasis by regulating the equilibrium 
between proliferation and cell death. Typical apoptotic cell death morphologies 
include cell membrane blebbing, cell shrinkage, membrane-bound apoptotic bodies, 
and chromatin condensation (Saraste and Pulkki 2000). Cells committed to apoptotic 
cell death will be recognized and engulfed by neighbouring immune cells to remove 
cell corpse. Apoptosis is relatively graceful and clean and does not involve the 
inflammatory response usually associated with necrotic cell death, (Krysko, Vanden 
Berghe et al. 2008). For this reason, apoptosis has been favoured by researchers for 
understanding the underlying molecular mechanism that govern the initiation, 
execution and regulation of this cell death modality. As such, until now apoptosis is 
considered as the preferred mechanism for chemotherapeutic reagents-induced cell 
death. Therefore, the key apoptotic machineries and signaling pathway that regulate 
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apoptosis have been of novel chemotherapeutic drug discovery and development 
(Kaufmann and Earnshaw 2000). 
There are two major apoptosis signaling pathways, i.e., the death receptor (extrinsic) 
pathway and the mitochondrial (intrinsic) pathway (Hengartner 2000, Billen, Shamas-
Din et al. 2008) see Figure A. The extrinsic pathway is triggered by the binding of an 
extracellular ligand to a cell death receptor(s) residing on the plasma membrane; 
whereas, activation of intrinsic pathway is more prone to intracellular stress, such as 
DNA damage, acute reactive oxygen species (ROS) insult, UV radiation, viral 
infection and mitochondrial targeted agents (Simon, Haj-Yehia et al. 2000) (Roulston, 
Marcellus et al. 1999, Norbury and Zhivotovsky 2004). Activation of either pathway 
will eventually converge on activation of caspases through proteolysis, a family of 
aspartate-specific cysteine protease, which are responsible for the biochemical and 
morphological features of apoptosis by cleaving a range of target substrates (Alnemri, 
Livingston et al. 1996) (Danial and Korsmeyer 2004). Mammalian caspases involved 
in apoptotic execution can be subdivided into two functional groups, (i) initiator 
caspases (Caspase-2, -8, -9, -10) and (ii) effector caspases (Caspase-3, -6, -7). 
Caspases are firstly synthesized as precursors, activation of effector caspases needs 
initiator caspase cleavage, while initiator caspase are capable of auto-proteolytic 
activation (Degterev, Boyce et al. 2003).  
 
2.1.1 The extrinsic pathway of apoptosis  
The transmission of cell death signal from a cell’s exterior to interior is mediated by a 
group of cell death receptors on the cell surface. Cell death receptors belong to the 
tumor necrosis factor receptor (TNFR) gene superfamily, such as CD95 (APO-1/FAS), 
TNFR and TRAIL (DR4, DR5) receptors (Locksley, Killeen et al. 2001). Individual 
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member of TNFR family recognizes and binds to its specific ligand with exclusivity 
through a cysteine rich extracellular subdomain. Apoptosis-inducing ligands (TNF, 
TRAIL, Fas) characteristically initiate signaling via death receptor oligomerization. 
Death receptors contain a homologous cytoplasmic sequence termed the “death 
domain” that in turn facilitates the recruitment of specialized adaptor proteins, FADD 
(Fas-associated cell domain) or TRADD (TNF receptor-associated death domain) 
(Chinnaiyan, O'Rourke et al. 1995). Bound adaptor protein conscript initiator caspases 
(caspase-8/caspas-10) to form a receptor-FADD/TRADD-Caspase8/10 protein 
assembly termed as the DISC (death-inducing signaling complex) (Kischkel, 
Hellbardt et al. 1995). Recruited pro-caspase 8 undergoes oligomerization and 
activation by autocatalysis. At the execution phase, caspase 8 can directly activate 
effector caspases, such as caspase 3, 6, 7 by proteolysis cleavage, which is also 
classified as type I cell death pathway. Activated caspase 3 ultimately leads to 
morphological hallmarks of apoptosis, like DNA fragmentation, cell membrane 
shrinkage, and others. Another parallel cascade of caspase 8-stimulated apoptosis is 
via cleavage of the Bcl-2 family protein, Bid, which mainly happens in type II cell 
death. Bid is a pro-apoptotic BH3-only protein that bridges the crosstalk between the 
extrinsic pathway and the mitochondria cell death pathway (Roy and Nicholson 2000). 
Truncated Bid translocates from cytosol to mitochondria and becomes an integral 
mitochondrial membrane protein that induces mitochondrial outer membrane 
permeabilization (MOMP), a crucial event in apoptosis (Roy and Nicholson 2000, 




2.1.2 The intrinsic pathway of apoptosis 
Intrinsic stimuli such as DNA damage, ROS, ER stress, growth factor withdraw and 
others generate integrated signals converging on induction of MOMP, an event 
considered as “point of no turn” during apoptosis (Kroemer, Galluzzi et al. 2007). 
MOMP is momentous in cell-death decision making, as it results in release of pro-
apoptotic proteins cytochrome c, AIF and Smac/Diablo from the mitochondria 
intermembrane space (IMS) into cytosol (Li, Nijhawan et al. 1997). Diffusion of 
cytochrome c to cytosol, where it binds to apoptotic protease-activating factor 1 
(Apaf1) and cofactor dATP to form a large apoptosis-activating complex termed 
“apoptosome” that subsequently activates initiator and effector caspases, normally 
caspase 9 and caspase 3, respectively (Zou, Henzel et al. 1997, Zou, Li et al. 1999).  
A coordinated effort between B cell lymphoma 2 (BCL-2) family proteins is essential 
for permeabilization of OMM. The Bcl-2 family proteins may be divided into anti-
apoptotic proteins containing four bcl-2 homology domain (BH1-4), such as Bcl-2, 
Bcl-xL; pro-apoptotic multi-domain protein (BH1, 2, or 3), like Bax and Bak; and 
pro-apoptotic BH3-only proteins encompass only one BH3 domain, examples are Bid, 
Bim, Bad, etc (Letai, Bassik et al. 2002). MOMP is tightly regulated by an 
equilibrium of pro-apoptotic proteins and pro-apoptotic proteins (Brunelle and Letai 
2009). In resting cells, pro-apoptotic protein Bax and Bak are inactive and sequestered 
in cytosol and OMM, respectively. Following apoptotic stimuli, activation of certain 
BH-3 only proteins such as abovementioned Bid is required to trigger pro-apoptotic 
protein conformational change (both Bak and Bak) and insertion into outer membrane 
of mitochondria (for Bax only, Bak constitutively associates with OM). Anti-
apoptotic members Bcl-2 or Bcl-xL bind directly to and inhibit pro-apoptotic activity 
of Bak and Bak, thereby preventing MOMP and downstream apoptotic cell death 
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execution. The imbalanced overexpression of anti-apoptotic Bcl-2 proteins over the 
pro-apoptotic counterparts accounts chemotherapy resistance in a wide variety of 
human cancers (Chen, Willis et al. 2005).  
 
Figure A. Intrinsic and extrinsic pathways of apoptosis. (Youle and Strasser 2008). 
The figure was reproduced upon permission from Nature Reviews Molecular Cell 
Biology, permission license number provided 3542371242873 
 
2.2 Necrosis 
For the past couple of decades, while apoptosis has taken the centre stage as the 
principal mechanism of programmed cell death in mammalian cells and well 
described at genetic and biochemical levels, necrosis has been relegated to an 
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accidental form of death with little physiological significance. Necrosis, originated 
from the Greek word ‘nekros” for corpse, has been used to describe a form of cell 
death which is uncontrolled and pathological. Lacking of a molecular signature, 
necrosis is morphologically defined by loss of plasma membrane integrity, translucent 
cytoplasm, intracellular organelles swelling by light and electron microscopy (Rello, 
Stockert et al. 2005). Despite the common belief that necrosis is a result of 
bioenergetic catastrophe and an event of no good deed to the organismal homeostasis, 
accumulating evidence suggests that necrotic cell death not only occurs in a regulated 
manner but also has a prominent role in multiple physiological and pathological 
processes (Festjens, Vanden Berghe et al. 2006). Various forms of cell death such as 
oncosis, pyroptosis, autosis, necroptosis, mitotic catastrophe and autophagy cell death 
which are non-apoptotic and display aspects in programmed cellular suicide have 
been classified under the category of programmed necrotic cell death. A diverse range 
of triggers include excitotoxins, ligation of cell death receptor (eg: TNF in 
combination of ZVAD), DNA alkylating damage and inactivation of Na+,K+-ATPase 
have been reported to induce regulated necrotic cell death under defined conditions 
(Zong, Ditsworth et al. 2004, Bano, Young et al. 2005, He, Wang et al. 2009, Liu and 
Levine 2014). Numerous studies have also highlighted the physiological and 
pathological role of necrosis in a number of disease processes, including vascular-
occlusive disease, neurodegenerative diseases, infection, inflammatory diseases and 
cancer (Majno and Joris 1995, Proskuryakov, Gabai et al. 2002, Yuan, Lipinski et al. 
2003). As a consequence, it is to be noted that engaging auxiliary therapeutic 
strategies aiming at engaging cell death pathways, other than apoptosis, are beginning 
to get significantly more attention. This is further reinforced by the invariable 
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association of apoptosis resistance with the process of carcinogenesis and it’s 
progression/spread.  
2.2.1 Necroptosis 
Necroptosis is a form of regulated necrotic cell death that can be activated through 
ligation of cell death receptor by their respective ligands, such as members of tumor 
necrosis factor (TNF) family (TNF alpha, TRAIL), Fas ligand, toll-like receptors, 
under apoptosis deficient circumstance. Other physical and chemical stresses could 
also initiate necroptosis, including chemotherapeutic reagents, ionizing radiation, 
photodynamic therapy as well as calcium overload. (Holler, Zaru et al. 2000, Kemp, 
Kim et al. 2003, He, Liang et al. 2011, Fulda 2013). In apoptosis prevented conditions 
(by using ZVAD inhibitor or siRNA silencing of caspase), necroptosis stimuli 
modulate the activation of necroptosis through phosphorylation of receptor-interacting 
protein kinase 1 (RIP1), the most crucial upstream mediator of necroptosis, which 
mediates the subsequent interaction of RIP1 and RIP3 to form a complex named 
“necrosome” (He, Wang et al. 2009, Zhang, Shao et al. 2009). Necrosome further 
recruits and activates an important substrate of RIP3, the mixed lineage kinase domain 
like protein (MLKL) which has been shown to target functional downstream targets 
on cellular organelles such as mitochondria/lysosomes (Sun, Wang et al. 2012, Wu, 
Huang et al. 2013) (Figure B). Blocking the kinase activity of RIP1 by the allosteric 
inhibitor necrostain-1 or genetic silencing approach inhibits the activation of 
necroptosis and allows cell survival and proliferation in the presence of cell death 
stimuli, an indicator of RIP1-dependent necroptosis (Holler, Zaru et al. 2000, Festjens, 
Vanden Berghe et al. 2007). The revelation of necroptosis inverts the traditional 
believe that necrosis is merely a passive form of cell death and gains its appreciation 





Figure B. The RIP1/RIP3 necrosome forms a functional amyloid signaling 
complex required for programmed necrosis (Li, McQuade et al. 2012). The figure 
was reproduced upon permission from Cell, permission license number provided 
3602830199029 
 
2.2.2 Autophagy  
Another form of programmed necrosis that has drawn considerable attention among 
researchers is “autophagy cell death”, largely due to the increasing evidence in 
understanding the molecular basis of autophagy per se over the past decades 
(Klionsky 2008, Levine and Kroemer 2008). However, the role of autophagy in 
promoting cell survival or cell death is rather circumstantial and still a matter of 
debate (Xu, Wu et al. 2013). Before we discuss on this intricate topic on autophagy-
mediated cell death, a brief summary on the well-established process of autophagy 
formation will be firstly introduced.  
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2.2.2.1 Dynamic process of autophagy 
Autophagy, a synonym of “eating of self”, is an evolutionarily conserved catabolic 
process whereby unwanted, dysfunctional and malicious cellular components are 
engulfed to autophagosomes and eventually delivered to lysosomes for degradation. 
This self-degradative process is critical for balancing the source of cell energry at 
critical times when the cells are facing a nutrient crisis (Yorimitsu and Klionsky 2005) 
(Mizushima, Levine et al. 2008). Autophagic process is precisely and collaboratively 
controlled by a series of autophagy-related genes (ATG), which is conserved in 
diverse orgnisms like yeast, flies and mammals that all carry the orthologous genes of 
ATG (Klionsky, Bruford et al. 2012).  The dynamic event of autophagy occurs in a 
sequential order, which are induction of phagophore, autophagosome formation, 
autolysophagosome fusion and degradation (He and Klionsky 2009). As illustrated in 
Figure C, autophagy begins in a stepwise manner by the engulfment of cytosolic 
contents by an isolated membrane (phagophore) which sequesters cellular cargo in a 
double-membrane vesicle termed the autophagosome. This initial step requires 
negative regulation of mammalian target of rapamycin (mTOR) via ULK1/Atg1 
(Kuroyanagi, Yan et al. 1998). Repression of mTOR facilitates re-association of 
dephosphorylated Atg13 and Atg1 to form a complex which stimulates downstream 
signaling to induce autophagy (Simonsen and Tooze 2009) (Figure C step1). 
Following this, vesicle nucleation and elongation of autophagosomes is mediated by 
Beclin1/Vps34 class III phosphatidylinositol 3-kinase (PtdIns3K) complex and two 
ubiquitin-like conjugation systems (Atg12-Atg5 and LC3/Atg8), respectively. 
Activation of mammalian Vps34  initiates a multiprotein complex formation by 
recruiting three important players, beclin-1 (Becn1; the mammalian orthologue of 
Atg6), UVRAG (UV irradiation resistance-associated tumor suppressor gene) and a 
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myristylated kinase, which acts as a command headquarter governing vesicle 
nucleation (Vps15) (step 2). Atg12, an ubiquitin-like protein identified as a crucial 
component of autophagy, which covalently binds to Atg5 with the help of E1-like 
enzyme Atg7 and E2-like enzyme Atg10. The Atg12-Atg5 ubiquitin-like conjugation 
system promotes elongation and closure of the autophagosome (step3) (Geng and 
Klionsky 2008). The other ubiquitin-conjugation system involves the conjugation of 
LC3/Atg8 (LC3 is one of the mammalian homologues of Atg8) to lipid 
phosphatidylethanolamine (PE) (Ichimura, Kirisako et al. 2000). Nascent LC3/Atg8 
proteins are firstly synthesized as precursors and immediately cleaved by Atg4, a 
specific cysteine protease recognizes the C terminus of LC3/Atg8 (Nakatogawa, 
Ichimura et al. 2007). Cleaved LC3/Atg8 subsequently conjugates with PE via 
sequential action of ubiquitin-like enzymes, the E1-like enzyme Atg7 and the E2-like 
enzyme Atg3. Lipid-conjugated LC3 (named LC3-II) resides on both inner and outer 
membranes of autphagosomes and serves as a biochemical marker for autophagy 
detection (step4) (Ichimura, Kirisako et al. 2000). Lipid conjugation leads to LC3 
conversion and modifies its electrophoresis motility on SDS gel, where a shifted band 
near LC3 is expected by western blot analysis. Exogenous introduction of a GFP-LC3 
fusion protein is another common tool in visualization of autophagosome formation. 
Lipidation of LC3 and it recruitment from cytosol to autophagosome membrane 
provides a shift of diffuse to fluorescent puncta (Mizushima, Yoshimori et al. 2010). 
Lastly, autophagosome maturation by fusion with lysosomes to create autolysosomes 
where degradation of luminal contents takes place, which is also called “autophagy 





Figure C. Autophagy and its inhibitors. (Maiuri, Zalckvar et al. 2007). The figure 
was reproduced upon permission from Nature Reviews Molecular Cell Biology, 
permission license number provided 3542380238769 
 
2.2.2.2 Autophagy as a pro-survival mechanism 
Despite the explosive increase in understanding the mechanism of autophagy at both 
cellular and molecular levels, a highly debatable discrepancy on the role of autophagy 
in cell fate decision still exists (Kang, You et al. 2007) (Baehrecke 2005). Based on a 
vast number of studies, two hypotheses on the role of autophagy have emerged: 
autophagy assists in cell death or autophagy protects cells from death. Researchers 
holding either opinion have endeavoured to convince the counterparty with their 
persuasive evidence.  
In low eukaryotics and vertebrates, such as yeast, worms, flies and mice, 
physiological level of autophagy can function as a pro-survival mechanism for cells 
and organisms in energy deficient circumstances (Tsukada and Ohsumi 1993, 
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Melendez, Talloczy et al. 2003, Kuma, Hatano et al. 2004). Once the supply of 
environmental nutrients runs low, autophagy can generate a source of cellular 
metabolites by recycling amino acids from unwanted or misfolded proteins to sustain 
physiological activity and maintain cellular homeostasis. Glucose deprivation, amino 
acid starvation, ROS, ER stress and other forms of cellular stress stimuli could all fire 
the engine of autophagy. This cytoprotective response of autophagy as a ‘housekeeper” 
also exists in human cells. An inducible autopahgy exerted to protect cells from 
pathological injuries has been detected in many human diseases, such as 
neurodegenerative disease (Alzheimer’s disease, Parkinson’s disease), cardiovascular 
disease (Martinet, Knaapen et al. 2007) and cancer (Grasso, Garcia et al. 2012). Many 
studies have demonstrated that in the absence of apoptosis, genetic inactivation of 
autophagy either by constitutively activation of mTOR pathway or siRNA 
interference of Atg5 or 7 deters the cell survival upon nutrition deprivation (Lum, 
Bauer et al. 2005, Mathew, Kongara et al. 2007). Autophagy exploited by cancer cells 
as a mean to overcome the harsh tumor microenvironment and promote tumor growth 
is believed to be one of the contributors to poor chemotherapy efficacy in the clinic.  
 
2.2.2.3 Autophagic cell death 
Autophagy is a naturally built in attribute that is utilized by cells to combat energy 
deficit and survive. It is seemingly difficult to reconcile its role as an execution 
commander of cell death. The concept of autophagy cell death was initially brought 
up based on the morphological observations of an increased autophagy markers in 
dying cells and was subsequently regarded as necrotic cell death (Schweichel and 
Merker 1973). This definition based on morphological features, however, lacks 
fundamental evidence at molecular level to convince the causive role of autophagy in 
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cell death. Accumulation of autophagosomes in cells may not be an absolute 
indication of increased autophagy flux, but rather, due to a possible blockade of 
autophagosome maturation. In that sense, autophagy is not a murder of cell death but 
an insignificant observer. Compounding the intrigue is the interplay between 
autophagy and apoptosis (Baehrecke 2005). Usually autophagy is initiated as a first 
line of defence in cells when facing a stressful condition. However, when the cellular 
stress exceeds the cellular capacity and becomes deleterious, autophagy may no 
longer be of much help for cell survival and cells are sent down the path to apoptosis 
(Marino, Niso-Santano et al. 2014). Of note, once cells commit suicide, apoptosis 
may in turn suppress autophagy by caspase-mediated cleavage of autophagy core 
machineries, such as Atg5 and p62 (Herzog, Yang et al. 2012). While, autophagy and 
apoptosis occur in the same cells, cooperate, suppress and assist each other, whether 
autophagy acts as a killer, an accomplice or merely a bystander remains debatable. 
Also, distinguishing autophagic cell death from apoptosis or other forms of necrotic 
cell death further contributes to the controversy regarding the role of autophagy in cell 
death (Shen and Codogno 2011). To that end, a new functional definition of 
autophagy cell death has been established and well-recognized among researchers. 
Autophagy cell death is a form of programmed necrosis, in which autophagy per se is 
the mechanism of cell death. To define cell death as autophagy mediated, it must meet 
a few criteria: (i) Cell death occurs without involvement of apoptosis machineries, (ii) 
There is an increase of functional autophagy flux, in another word, a dynamic 
autphagosome maturation process, and (iii) Pharmacological and genetic intervention 
of essential components of autophagy is able to reverse the cell death event. 
Commonly used inhibitors for blocking different steps of autophagy include the type 
III Phosphatidylinositol 3-kinases (PI-3K) inhibitor, 3-Methyladenine (3-MA) and 
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wortmannin; the H+-V-ATPase inhibitor, Bafilomycin A1, and the lysosomotropic 
agent chloroquine (See Figure C).  
 
2.2.3. Ca2+ as mediators of necrotic cell death 
One of the most common players in necrotic cell death is calcium. Calcium is an 
essential elements in most of the organisms governing a host of vital cellular activities 
ranging from fertilization, synaptic transmission, gene transcription, hormone 
signaling to cell death. A finely tuned calcium singaling is fundamental for 
manipulation of cell fate in living organisms, positively and negatively. Alterations in 
calcium homeostasis has been implicated in both pro- and anti-apoptotic events and is 
also regarded as a key factor for activation of necrotic cell death and autophagy 
(Fleckenstein, Janke et al. 1974, Trump and Berezesky 1996, Nicotera, Leist et al. 
1999, Hoyer-Hansen, Bastholm et al. 2007).  
The intracellular level of free calcium is finely orchestrated by the two major 
organelles, endoplasmic reticulum and mitochondria, that are responsible for 
sequestering calcium and thereby maintaining a very low cytosolic concentration of 
calcium. The most important intracellular calcium store in most mammalian cells is 
endoplasmic reticulum (ER). Calcium sensing, sequestration, and release from the ER 
is finely regulated by a set of calcium pumps and receptors expressed on the ER 
membrane such as the ryanodine receptor, the IP3 receptor, and ATP-dependent 
active transport pumps, referred to as sarcoplasmic reticulum calcium transport 
ATPase (SERCA) pump (Berridge 1993, Sanderson 1995). A classical experimental 
strategy to highlight the importance of ER as a major intracellular calcium store is the 
use of thapsigargin which functions by blocking the active transportation of calcium 
through SERCA pumps (Michelangeli, Liprandi et al. 1995). A number of 
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observations have also provided evidence linking ER stress to dysregulation of 
calcium homeostatiss. This connection between the ER and calcium in initiating 
signals that lead to cell damage or death have also been associated with oxidative 
stress signaling (Berridge 1998). Whereas ER plays a critical role in maintaining the 
balance between high organelle calcium (1mM) and low cytosolic calcium (100nM), 
this is ably facilitated by an equally efficient capability of mitochondria to perform a 
similar function (Clapham 2007). 
The role of mitochondria in buffering calcium has been well highlighted by elegant 
studies demonstrating that elevated cytosolic calcium following efflux from the ER 
can be sequestered readily by mitochondria (Kirichok, Krapivinsky et al. 2004). This 
is accomplished by a very close communication between ER and mitochondria to 
allow for the maintenance of steady state of cytosolic calcium (de Brito and Scorrano 
2008) (Santo-Domingo and Demaurex 2010). Whereas, the mitochondria is a 
powerful intracellular store of calcium, studies have also demonstrated that 
overloading of mitochondria with calcium could have catastrophe consequence to 
mitochondrial function. Kroemer et al demonstrated decades ago that overloading 
mitochondrial with calcium resulted in a rapid opening of mitochondria permeability 
transition pore (MPT) which dissipated the inner membrane potential and led to a 
cascade of events culminating in various forms of cell death, including apoptosis and 
necrosis (Kroemer, Galluzzi et al. 2007) (Pinton, Giorgi et al. 2008). The same group 
also highlighted that lysosomal membrane permeability (LMP) preceded the induction 
of mitochondrial membrane permeability (MMP) thereby suggesting a second 
communication between lysosome and mitochondria in addition to mitochondria and 




2.2.3.1 Ca2+ vs lysosomal cell death 
In has been recently appreciated that lysosomes also function as a significant source 
of intracellular calcium (Duman, Chen et al. 2006). Studies have shown that luminal 
calcium level in lysosomes is surprisingly comparable to that of the ER (Watanabe 
2007) (Lloyd-Evans, Morgan et al. 2008). More recent reports provide testimony for 
the existence of specific calcium transport channels at least in some species, therefore 
suggesting a dynamic regulation of intralysosomal calcium. What is not clear is the 
various mechanisms involved in the uptake as well as the release of calcium from the 
lysosomes. However, with respect to the later, evidence is accumulating for the 
presence of specific calcium export mechanisms within the lysosome, such as TRP 
family, TRP-ML (Venkatachalam and Montell 2007) (Brailoiu, Churamani et al. 
2009). In a nut shell, it appears that nature has provided multiple levels of regulating 
free cytosolic calcium to prevent the execution of cell death upon accidental or 
induced leakage of calcium from one of these organelles.  
Lysosomes are the digestive organelles responsible for the degradation and removal of 
unwanted cellular components (James 1974). This is accomplished by a wide array of 
enzymes that cleave various substrates, such as cathepsins, hydrolase, etc. The 
lysosomes generally function at very low acidic pH and therefore any stimulus that 
alters the [H+] in the lysosomes can drastically affect the lysosome functions. Of note, 
lysosomes are a central player in the autophagosome maturation and degradation of 
the cellular cargo. A few human diseases have been associated with abnormal 
function of lysosomes, lysosomal storage disease Niemann-Pick disease, type C, 
Fabry disease, and Hunter syndrome (Chang, Reid et al. 2005, Wraith, Scarpa et al. 
2008). A number of years ago, LMP was shown to be an early signal of mitochondria-
induced cell death. In this report, the authors clearly demonstrated that the 
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permeability of lysosome membrane was compromised before the induction of 
mitochondrial permeability, suggesting an upstream role for the lysosomes in the 
execution signal (Boya, Andreau et al. 2003).  Consistent with that, Ulf T. Brunk and 
colleagues showed that the lysosome was an important mediator of cell death in a 
variety of model systems (Yuan, Li et al. 2002, Terman, Gustafsson et al. 2006).  As 
for the role of lysosome in cell death signaling, one could speculate based on 
published reports that the lysosomes could trigger death signaling through a variety of 
mechanisms, such as release of enzymes like cathepsins, altering intracellular pH 
homeostasis and an increase in intracellular ROS production (Stoka, Turk et al. 2007, 
Boya and Kroemer 2008, Lin, Epstein et al. 2010). What is not presently clear is that, 
as mentioned in the preceding section, lysosomes are a major source of intracellular 
calcium but their role in calcium-dysregulated cell death signaling is not being well 
understood. This begs the question vis-à-vis the active or passive role of lysosomes in 
cell death signals directly induced by dysregulation of intracellular calcium.  
 
2.2.3.2 Lysosomal calcium efflux 
Lysosomal calcium efflux, same as calcium efflux from ER or cytosol, is mediated by 
a group of calcium ion channels localized to the vacuole membranes (Figure D). 
Transient receptor potential (TRP) channels are a large superfamily of distantly 
related cation channels and are generally described as calcium-permeable channels in 
most cells. Mammalian TRP channels contain six transmembrane domains that 
assemble as tetramers to form a calcium permeable pore (Clapham 2003). The 
mucolipin protein family (MCOLN1, MCOLN2, MCOLN3), also known as TRPMLs, 
is the only subfamily of TRP channels restricted to the intracellular vesicles. 
TRPML1, so far is the best characterized TRP channel located at the lysosomal 
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vacuoles, the localization of the other two family members (TRPML2, TRPML3) is 
less clear(Clapham 2003). In Caenorhabditis elegans, mutation of TRPML1 
homologue cup-5 has been shown to result in excessive accumulation of lysosome 
which eventually leads to loss of cell viability in multiple cell types (Hersh, Hartwieg 
et al. 2002). TRPML1 mutation associated with lysosomal storage disorder, an 
autosomal recessive, neurodegenerative human disease (Mucolipidosis type IV) is 
another remarkable finding in highlighting its importance in lysosome function and its 
maintenance (Sun, Goldin et al. 2000, Bach 2001, Bach 2005). Niemann–Pick (NP) 
disease is a group of severe metabolic disorders that fail in late endosomes-lysosomes 
fusion, a process known to be calcium dependent, and allows lipid accumulation in 
the lysosome. Lysosomal calcium released predominantly via TRPML1 channel is 
significantly reduced in NP cells. Overexpession of TRMPL1 or increasing its activity 
could successfully rescue Ca2+-dependent lysosomal trafficking defects and reduce 
cholesterol accumulation (Shen, Wang et al. 2012).  
Another group of ion channels in governing calcium release from acidic 
compartments is two-pore channels (TPCs). TPCs are so named because of their 
primary protein structure with two putative pore-forming repeats, which are 
architecturally common to many voltage-gated channels (Ishibashi, Suzuki et al. 
2000). TPCs-mediated organellar calcium release is nicotinic acid adenine 
dinucleotide phosphate (NAADP)-dependent, a relatively new Ca2+ mobilizing second 
messenger that exists in a variety of mammalian cell types and selectively targets on 
acidic calcium stores (Calcraft, Ruas et al. 2009). TPCs serve as components of 
NAADP receptors and appear to be exclusively localized to the endolysosomal 
system. Lysosomal calcium release via TPCs in response to NAADP could further 
evoke a secondary phase of calcium release from endoplasmic reticulum by InsP3Rs 
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(Calcraft, Ruas et al. 2009, Galione, Morgan et al. 2010). Besides aforementioned two 
major calcium channels TRPMLs and TPCs in regulation of lysosomal calcium efflux, 
inositol trisphosphate (InsP3Rs) and ryanodine receptors (RyRs) that are 
predominantly located within the ER membrane have also found their additional 
subcellular location in acidic calcium stores and orchestrate lysosomal calcium 
mobilization (Walensky and Snyder 1995) (Yoo 2010).  
 
Figure D. Calcium release from acidic calcium stores. (Patel and Docampo 2010). 
Schematic of an acidic calcium store depicting (top) calcium-permeable channels that 
mediate calcium release, and (bottom) V-ATPases and V-PPases responsible for 
acidification. The figure was reproduced upon permission from Trends in Cell 
Biology, permission license number provided 3598520571828 
 
2.2.3.3 Calcium uptake into acidic calcium stores 
The principle calcium channels in ruling lysosomal calcium release have been 
extensively characterized over the past decades with an evolving understanding of 
their biological activities. Compared to this, how do acidic calcium stores uptake and 
sequester intracellular calcium into their luminal compartments is poorly assessed and 
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remains less well characterized, especially in mammalian cells. Calcium ATPase 
pumps found in membranes of various organelles and plasma membrane facilitate 
calcium uptake against its concentration gradient from a low calcium store to a high 
calcium organelle (Figure E). Similarly, subfamily of plasma membrane calcium 
ATPase (PMCA) have also been found in the acidic calcium vacuoles of yeast, 
Dictyostelium and plant; the presence of PMCA subtype in animal cells still remains 
unclear (Cunningham and Fink 1994, Moniakis, Coukell et al. 1999, Geisler, Axelsen 
et al. 2000). 
Another category of calcium porters transporting calcium from cytosol to luminal 
compartments is calcium-hydrogen exchangers (CAXs) by utilizing the high 
concentration gradient of protons across the membranes of acidic calcium stores 
(Shigaki, Rees et al. 2006). Transport of calcium ion against its electrochemical 
gradient is powered by the flow of protons within its electrochemical gradient. CAXs 
has been described in the acidocalcisomes of some low eukaryotic organisms and 
plant vacuoles, some of which have been functionally characterized. Despite some 
evidence of CAXs encoding genes are present in fish and amphibians genome, they 
are absent in animal genomes (Cunningham and Fink 1996, Hirschi, Zhen et al. 1996, 
Shigaki, Rees et al. 2006). Neither Ca2+-ATPase pumps nor calcium-hydrogen 
exchangers is detectable in animal cells, which adds more complexity for researchers 
to understand the molecular mechanisms of calcium uptake into acidic compartments. 
Studies from Swanson’s group by using pharmacological manipulation on mouse 
marcrophages had firstly demonstrated that the dynamic movement of calcium ion 
into lysosomes is intralysosomal pH-dependent (Christensen, Myers et al. 2002). 
Increasing lysosomal pH through inhibition of H+-V-ATPase mediated by 
bafilomycin A1 or neutralization of proton concentration with ammonium chloride, 
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decreased luminal calcium concentration in the acidic compartments (Christensen, 
Myers et al. 2002). This observation was reinforced with re-acidification of lysosomes 
experiment which allowed a rapid restoration in intralysosomal calcium concentration. 
This elegant study has uncovered that the lysosomal calcium concentration is tightly 
maintained and regulated partially by a dynamic proton gradient across lysosome 
membrane. Seeing that there is no evidence of CAXs in animal genomes, one 
possibility to explain this paradox is that, instead of restoring to a single 
protein/exchanger, CAXs activity might be achieved by a concerted activity of both 
sodium-hydrogen exchangers and sodium-calcium exchangers. Overall, the 
synergistic collaboration of cation exchangers results in a net effect of calcium 
transport into the lysosome and proton out of the lumen (Patel and Docampo 2010).  
 
Figure E. Calcium transport in to acidic calcium stores. (Patel and Docampo 
2010). Schematic of an acidic calcium store depicting calcium pumps and exchangers 
that mediate (top) calcium uptake and (bottom) V-ATPases and V-PPases responsible 
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for acidification. The figure was reproduced upon permission from Trends in Cell 
Biology, permission license number provided 3598520571828 
 
3. Resistance to apoptosis as a hallmark of cancer 
3.1 Cancer hallmarks 
The idea of “cancer hallmark” was firstly fostered at the turn of the millennium by 
Douglas Hanahan and Robert Weinberg in generalizing the common biological traits 
in cancer cells that govern the multistep development of carcinogenesis (Hanahan and 
Weinberg 2000). In this most highly cited paper, cancer hallmarks were initially 
introduced to comprise six alterations in cellular physiology that were pivotal to 
transform a normal cell into malignant: (1) Cancer cells possess autonomy in 
generating their own growth signals (self-sufficiency in growth signals); (2) Cancer 
cells are resistant to anti-growth signals that might suspend or block cell proliferation 
process (insensitive to anti-growth signals); (3) Cancer cells are capable of escaping 
from cell death execution (evading apoptosis); (4) Cancer cells are immortal that 
divide infinitely and grow in an uncontrolled fashion (limitless replicative potential); 
(5) Cancer cells activate angiogenesis activator and encourage new blood vessels 
growth to supply nutrients for tumor progression (sustained angiogenesis); (6) 
Primary tumors may not be confined to in situ but sooner or later spread out to invade 
the surrounding tissues or migrate to a distant site (metastasis) via bloodstreams and 
form new colonies (Hanahan and Weinberg 2000) (Figure F). Just after a decade ever 
since then, in an updated publication, the same pioneer reseacheres have extended the 
concept of cancer hallmark by adding another two hallmarks of potential generality 
onto this list. Cancer cells adjust their energy metabolism largely to glycolysis in 
anaerobic conditions (reprogramming of energy metabolism) and acquire the ability to 
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evade immune surveillance and destruction by dismantling the components of 
immune system (immunoevasion) (Hanahan and Weinberg 2011).  
 
 
Figure F. The hallmarks of cancer. (Hanahan and Weinberg 2011). The figure was 
reproduced upon permission from Cell, permission license number provided 
3602830373711 
 
These complexities of cancer that hold important implications for successful cancer 
therapies have been increasingly recognized by cancer biologists and clinicians. The 
emergence of cancer hallmarks represents the most important and profound 
understanding of cancer, the principle of which has become the central focus in cancer 
research and clinical therapy. A growing hallmark-targeting therapeutics have been 
developed based on their effects on one or more hallmark capabilities. These targeted 
therapeutics has covered a wide spectrum of strategies involving inhibition of tumor 
cell growth, intervention of signal transduction, activation/re-sensitization of cell 
death, angiogenesis inhibition, modulation of gene expression, immunotherapy, and 
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others. All of these abovementioned strategies ultimately serve a single purpose that is 
to block cancer cell growth and survival. 
 
3.2 Evasion of cell death-a barrier in cancer chemotherapy 
Despite the conceptual progress in cancer biology in the past decades and the rapid 
advances in clinical cancer therapy, the overall cancer mortality has not decreased 
appreciably. One of the most crucial impeding factors in the progress of cancer 
chemotherapy is the resistance to apoptotic cell death (Hanahan and Weinberg 2000, 
Hanahan and Weinberg 2011). As one of the cancer hallmarks, resistance to apoptosis 
has provided cancer cells a nature barrier to evade drug-induced execution and 
eventually lead to tumor mass growth. To overcome this physiologic barrier to cancer 
treatment, the underlying molecular mechanism of this death-avoidance capability in 
cancer cells has been extensively elucidated. Cell death resistance in cancer cells can 
be divided into intrinsic (innate) and acquired (adaptive). The former one is due to 
accumulated cellular defects that occur during the course of cancer progression, whilst 
the later one are acquired after exposure to chemotherapeutic reagents (Pommier, 
Sordet et al. 2004).  
Defects in apoptosis has evolved and accumulated in the multi-step development of 
carcinogenesis, which renders cancer cells not only with an intrinsic survival 
advantage, but also an inherent resistance to chemo-, radio-, or immunotherapy. 
Thereby, modulation of apoptosis machineries at different molecular levels to restore 
apoptosis capability in cancer cells serves as a first line strategy in cancer 
chemotherapy. Over the past decades, extensive evidence has accumulated in 
understanding the molecular mechanisms that are exploited by cancer cells to escape 
or circumvent apoptosis (Fulda 2009). One of the invariable findings in most of the 
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cancers is increased ratio of anti-apoptotic to pro-apoptotic Bcl-2 gene family 
members (Adams and Cory 2007). In intrinsic apoptosis pathway, most of the 
apoptotic signals will converge at mitochondria and trigger apoptogenic protein 
release upon mitochondria membrane permeabilization (MOMP). This process 
considered as a “point-of-no-return” requires pro-apoptotic protein Bax and Bak to 
from large oligomeric pores on mitochondria membrane (Boya and Kroemer 2008). In 
accordance with this, overexpression of anti-apoptotic Bcl-2 family proteins, such as 
Bcl-2, Bcl-xL counterbalances the pro-apoptotic effect exerted by Bax and Bak and 
hinders MOMP onset, a decisive event that delimits cell fate. Development of small 
molecule inhibitors specifically targeting Bcl-2 protein has been a successful anti-
tumor approach in a way, as these inhibitors are intended to reduce the apoptosis 
threshold in cancer cells by antagonizing anti-apoptotic proteins (Hann, Daniel et al. 
2008).  
Another condition of resisting apoptosis in cancer cells is via mutations in tumor 
suppressor proteins such as p53, a crucial apoptotic component involved in 
mitochondrial cell death circuit by transcriptional regulation of target pro-apoptotic 
genes (Benchimol 2001). As a transcription factor, p53 exerts anti-cancer functions 
via various mechanisms. Under the conditions of DNA damage, p53 activates DNA 
repair proteins to fix the damage and maintain genome integrity; however, once the 
DNA damage is sustained and irreparable, damaged cells will undergo p53-mediated 
apoptosis via the upregulation of a series of pro-apoptotic proteins, such as Bax, Puma, 
and Noxa, (Junttila and Evan 2009) (Benchimol 2001). Therefore, loss of function of 
p53 tumor suppressor gene promotes resistance to apoptosis in cancer cells (Oren and 
Rotter 2010). Additional inactivation of retinoblastoma protein (Rb), an important cell 
cycle regulator and tumor suppressor, leads to compromised cell cycle control and 
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creates a survival pressure for tumor cells to inactivate downstream p53-mediated 
apoptosis event (Symonds, Krall et al. 1994).  
Resistance to apoptosis in cancer cells can also be achieved by augmented AKT/PKB 
pro-survival siganlling pathway (Kim, Dan et al. 2005). Various growth factors, 
cytokines and hormones activate AKT signaling circuit that are involved in regulation 
of multiple biological processes including cell survival, cell proliferation and growth, 
and glycogen metabolisms. PTEN, a phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase, has been considered as a tumor suppressor protein which 
dephosphorylates phosphatidylinositol-3,4,5-trisphosphate (PIP3) and counteracts 
PI3K/AKT pathway (Chu and Tarnawski 2004). Loss of function of tumor suppressor 
gene PTEN indirectly activates AKT-mediated cell survival, and has been implicated 
in many human cancers. For instance, constitutive and inducible ATK activity brings 
about resistance to chemotherapy in human breast cancer cells (Clark, West et al. 
2002). PTEN-deficient tumor cells derived from PTEN knockout mice exhibiting 
robust AKT activity are resistant to apoptotic stimuli (Wu, Goel et al. 2003). Based on 
these observations, targeting on PI3K/PTEN-ATK axis has appeared as a rational 
strategy for anti-cancer drug development and cancer chemotherapy.  Moreover, AKT 
cell survival signaling is involved at multiple levels via a crosstalk between 
PI3K/ATK and MAPK (mitogen-activated protein kinases) pathways. In addition, the 
oncogene Ras sits at the crossroad upstream of both ATK and MAPK pathways 
actively governing cellular signals transduction in regulation of cell growth, 
differentiation, proliferation and survival (Goodsell 1999). Constitutive active Ras-
MAPK pathways has been found in various types of cancerous cells, in which H-Ras 
and K-Ras with tumorigenic potency were often detected (Harvey 1964). To date, no 
effective approach directly targeting on mutant Ras is available, notwithstanding the 
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recognition of Ras as an important anti-cancer target over the time. Most of the focus 
have been endeavoured on developing inhibitors that indirectly block the activation of 
Ras by selectively disrupting the association of Ras protein with the plasma 
membrane or downstream effector signalings Raf-MEK-MAPK, some of which are 
currently under clinic evaluations (Basso, Kirschmeier et al. 2006, Rowinsky 2006, 
Baines, Xu et al. 2011). 
 
3.3 Multidrug resistance (MDR) phenotype 
Another remarkable obstacle in cancer chemotherapy is multidrug resistance by which 
many types of cancer cells develop drug-insensitivity to avoid cell death (Gillet and 
Gottesman 2010). Solid tumors as well as hematopoeitic cancers usually consist of a 
pool of heterogeneous malignant cells, some of which are sensitive to chemotherapy 
drugs while some are relatively refractory. Upon cancer chemotherapy, drug-sensitive 
cells are more prone to cell death whilst leaving behind the drug-insensitive cells alive 
and proliferating (Krishna and Mayer 2000).  Thus, cancer cells that survive repeated 
drug treatment exhibit resistance not only to a single cytotoxic drug but to a wide 
range of drugs targeting on different signaling pathways and cellular components. 
Indeed, this is a common phenomenon that severely constrains the effectiveness of 
chemotherapy and accounts for the failure of cancer treatment in various forms of 
malignancies (Gillet and Gottesman 2010). Principle mechanisms of resistance to 
multiple classes of chemotherapy drugs share many features such as alterations in 
drug efflux mechanism by overexpression of ATP-binding cassette (ABC) transporter 
proteins, activation of detoxifying proteins, enhanced capability in DNA damage 
repair, and activation of pro-survival pathway as well as deficient or ineffective 
execution pathways (Gottesman, Fojo et al. 2002). Either one of these particular 
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mechanisms is capable of leading to a consequence of cross-class drug resistance that 
limits patient treatment options and accelerates disease progression with poor 
prognosis.  
Multidrug resistance proteins (MRP) function as ATP-dependent transporters that 
pump out chemotherapeutic drugs out of intracellular milieu into the extracellular 
environment and prevent the access of anticancer agents to their sites of action (Tan, 
Piwnica-Worms et al. 2000). Ample evidence has accumulated over the past decades 
to demonstrate a strong correlation between the expression of MRPs in malignant 
cells derived from pre-treated patient tumors and the severity of multidrug resistance 
(Juliano and Ling 1976, Debenham, Kartner et al. 1982, Trock, Leonessa et al. 1997). 
P-glycoprotein, also known as multidrug resistance protein 1 (MDP1) or ATP-binding 
cassette sub-family B member 1 (ABCB1), is one of the most representative and well-
studied MDR genes that extrudes anticancer drugs from cancer cells and indirectly 
eliminates chemotherapy efficacy (Perez 2009).  P-glycoprotein is ubiquitously 
expressed in tissues, clinical tumors and cancer cell lines and implicated in both de 
novo and acquired drug resistance. Inducible expression of p-glycoprotein in tumor 
cells after exposure to chemotherapeutic drugs represents a potential biomarker for 
drug resistance.  
In addition to MRP-mediated drug efflux, increased drug detoxification is considered 
as another important contributor to MDR in chemotherapy. In physiological 
circumstance, removal of toxic substances from a living organism is catalyzed by a 
battalion of detoxifying enzymes, such as glutathione-S-transferase (GST), Keap1-
Nrf2, superoxide dismutase (SOD) and NAD(P)H:quinone oxidoreductase (NQO), 
which play an vital role in protecting cells from environmental or intracellular stresses 
(Liska 1998). However, in cancerous condition, detoxification enzymes are hijacked 
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by cancer cells and misused to eliminate the cytotoxicity of chemotherapy. GST, the 
most prominent detoxification enzyme, catalyses the conjugation of glutathion (GSH) 
to a wide array of endogenous and exogenous substrates. Many anticancer drugs 
decompose into small metabolites containing electrophilic moiety can be recognized 
as GST substrates and detoxified through GST metabolism system (Kauvar, Morgan 
et al. 1998). Elevated level of GST has also been detected in many types of cancer and 
associated with increased resistance to cell death elicited by a variety of apoptotic 
stimuli (Tew 1994).  
Another mechanism protects cancer cells against cytotoxic chemotherapy, especially 
genotoxic agents, is the enhanced capability in DNA damage repair. Not surprisingly, 
under constant cellular stress and exogenous chemotherapeutic attack, cancer cells 
have evolved and developed multiple mechanisms to overcome DNA lesions and 
maintain its genome integrity (Mocellin, Bertazza et al. 2012) (Wirthner, Wrann et al. 
2008). The most representative example of this scenario is platinum resistance 
observed in various human cancers. Cisplatin, a platinum-based small compound, was 
firstly developed and applied as a first-line chemotherapy in a range of human cancers 
since 1960s (Rosenberg, Vancamp et al. 1965). Cisplatin strives its significant 
cytotoxicity by introducing DNA lesion and disrupting DNA structure in many forms 
of hardy malignant tumors, such as non-small lung cancer, breast cancer, head and 
neck cancer and glioma (Dasari and Tchounwou 2014). Cancer cells recognize drug-
induced DNA damage and activate multiple pathways of DNA repair to protect 
cellular injury. This self-repairing mechanism in cancer cells can limit the efficacy of 
cisplatin and other genotoxic agents, which eventually leads to cancer cell survival 
and continued proliferation. 
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3.4 New line of chemotherapy for activating alternative cell death pathways 
As mentioned above, cancer cells usually display faulty apoptotic pathways that 
contribute to the initiation and progression of carcinogenesis as well as resistance to 
chemotherapeutic agents. This acquired trait of apoptosis resistance is an invariable 
finding in most human cancers and creates a dilemma for the use of single agent 
strategies targeting one specific pathway (Hannun 1997).  To circumvent this problem, 
the current line of treatment involves the use of multiple agents directed at diverse 
signaling networks. Examples include the use of DNA damaging agents together with 
inhibitors of signal transduction such as MAPK or tyrosine kinase inhibitors.  While 
this approach has definitely improved patient response, however as most agents still 
rely upon a functional apoptotic pathway for the ultimate execution of the cells, the 
problem with chemotherapy resistance still limits the efficacy of treatment.  Moreover, 
an incomplete understanding of the precise mechanism of death execution and the 
lack of preclinical models of combination therapy contribute to inevitably short-lived 
success stories (Bell 2013).  As a consequence, a body of emerging evidence provides 
strong support for identifying agents with the ability to  engage non-apoptotic forms 
of cell death, like mitotic catastrophe, autophagy and necrosis, which would 
potentially be effective in cells where the apoptotic signaling has been compromised 
(Ricci and Zong 2006) (Tan and White 2008). To that end, a variety of targeted agents 
have been reported to initiating alternative programmed cell death, some of which are 
currently under clinical evaluation. ∆9-Tetrahydrocannabinol (THC), the main active 
component of marijuana, induces autophagy-mediated cell death in human glioma 
cells through stimulation of ER stress. (Salazar, Carracedo et al. 2009). TNF alpha in 
combination of caspase inhibitor z-VAD or IAPs antagonists has been shown to 
induce necroptotic cell death in advanced cisplatin-resistant ovarian cancers. Notably, 
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this pathway occurred selectively in apoptosis-resistant cells, suggesting a functional 
necroptosis pathway that might be exploited for future chemotherapeutic strategy 
(McCabe, Bacos et al. 2014). Most recently, inhibition of poly (ADP-ribose) 
polymerase (PARP) has been appreciated as an effective anticancer approach to target 
cancers with vulnerable genetic lesions, particularly in cells with defective 
homologous recombination (HR) repair pathway, such as inherited faults in human 
BRCA1 or BRCA2 genes (Patel, Sarkaria et al. 2011). Currently, several PARP 
inhibitors are already under clinical trials exhibiting exciting potential as a new class 
of chemotherapeutic drugs (Kaufman, Shapira-Frommer et al. 2014) (Sandhu, 
Schelman et al. 2013). 
 
4. Lanthanide “Rare Earth” metals as promising novel experimental compounds 
for cancer chemotherapy 
Among the chemotherapeutic agents employed in the clinic, platinum based gents 
such as cisplatin and oxaliplatin are the most commonly used drugs in most 
therapeutic regimens (Bruijnincx and Sadler 2008). However, the platinum-based 
suffer with the problems of drug resistance as well as off target toxicity. Therefore, 
efforts are geared at designing new “metal” compounds with better pharmacological 
properties and more effective antitumor activity (van Rijt and Sadler 2009). To that 
end, lanthanide rare earth compounds comprise of 15 different molecules with 
comparable properties, such as cerium, lanthanum, europium, gadolinium, ytterbium, 
erbium, lutetium, praesodymium, that are not as rare as suggested. Indeed, some 
lanthanides exist at almost comparable levels to those of other significant elements 
such as cobalt, selenium and platinum. Of note, some literature even indicates that 
lanthanides exist in nature more commonly than the most commonly used metal in 
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clinical chemotherapy, platinum. Most lanthanides exist as positively charged 
trivalent metals with oxidation number of +3, and generally appear in conjugates 
forms rather than as pure metals. Interestingly, praesodymium (Pr) also exist with 
oxidation number of +4 and is one of the lanthanides that forms stable compounds.  
Due to their physiochemical properties, various lanthanides have found application in 
a variety of industries, most importantly in metallurgy, cermaic and opto-electronic 
industries. These applications include enrichment of steel by removing oxygen, 
production of lasers and optical fibres, and in the generation of superconductors. The 
utility of these metal compounds is not restricted to metallurgy and electronics, but 
due to their remarkable optical and magnetic properties, lanthanides have also found 
application in the clinical imaging and diagnostic platforms (Palasz and Czekaj 2000). 
For example, some of these metals are excellent agents for radiographic application. 
In addition, their use in the clinical settings of radio-immunotherapy and 
photodynamic therapy agents have been recently explored (Zhang, Li et al. 2011, 
Naccache, Rodriguez et al. 2012). As a result of the recent heightened interest in their 
rather wide spread use in various industries and as potential imaging agents in 
diagnostic radiology, a close look at the effect(s) of these metals compounds on 
biological systems is imperative. In this regard, a few earlier studies have focused on 
looking at the toxicity of these compounds from the viewpoint that if these agents 
were to be introduced for human use it would be desirable to better understand their 
mode of action and potential toxicities (Haley 1991, Lizon and Fritsch 1999).  During 
the course of these studies, it was reported that lanthanides in general show 
predilection for accumulation in the liver, spleen and bones of animals (rats) when 
injected at relatively high concentrations (~20mg/kg) (Nakamura, Tsumura et al. 
1997).  Interestingly, while some level of induction of liver enzymes was reported as a 
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potential effect, another study demonstrated that co-delivery of lanthanides protected 
drug-induced liver injury by impacting on the cytochrome P450 enzymatic system 
(Strubelt, Siegers et al. 1980). Of particular note, these studies found a relationship 
between calcium loading in organs as well as blocking calcium channel activity and 
reducing the drug metabolizing activity as a potential mechanism of hepato-protective 
activity elicited upon the administration of 7-10mg/kg of gadolinium (Roland, 
Naziruddin et al. 1999). Also in studies on neuronal cells, the effect has been 
attributed to blocking of calcium channels and inhibiting calcium-mediated signaling, 
for instance in GABBA and glutamate receptor triggered responses (Kumamoto and 
Murata 1996).  Notably, this effect on calcium-channel activity has been proposed to 
be a function of similar ionic radii of trivalent lanthanides and calcium channels, 
however in separate experiments effects on ATP driven channels have also been 
observed (Lansman 1990). Based on some of these biological properties and early 
indications of cell penetrative activity, lanthanides have also been experimented as 
anti-cancer agents, such as in phase III clinical trials against metastatic brain cancer 
and non-small cell lung carcinoma (Fricker 2006). However, the precise mechanism 
of their anti-cancer activity at the molecular level remains poorly defined.   
As alluded to in the preceding paragraph, based on their diverse biological and 
chemical properties, lanthanides are being look at for their potential application in the 
clinical setting. Most of the data on effect on mammalian cells so far, albeit limited, 
has been predominantly reported with lanthanum and gadolinium.  Our group has 
been interested in understanding the biological properties of one of these lanthanides, 
Praesodymium (Pr). A colleague chemist in the laboratory synthesized a conjugate of 
Pr (Praesodymium-mercaptopyridine oxide; Pr-MPO) and its initial activity was 
studied on neuroblastoma cells.  This molecule was shown to have a mild activity to 
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activate the nuclear receptor PPAR-γ (peroxisome proliferation and activation 
receptor-gamma) and elicit anti-cancer activity against SHEP-1 cell line, the precise 
molecular mechanisms underlying the anti-cancer activity remained poorly 
understood. My interest in delving into the molecular mechanisms of this rare metal 
conjugate was intrigued by my initial findings that Pr-MPO elicited anti-cancer 
activity against a wide range of cells including cells that were rendered resistant to 
apoptosis by either the loss of pro-apoptotic proteins or the overexpression of anti-
apoptotic counterparts.  As such the overall goal of my project was to characterize the 
mode of cell death and identify the underlying mechanisms of the anti-cancer activity 
of this remarkable compound. With the impetus that understanding of the molecular 
pathways involved in alternative modes of cell death could have potential therapeutic 
implications in cancers that are rendered refractory to apoptosis inducers (as discussed 
in detail in preceding sections), I hope that this work could push the field forward in 

















Resistance to apoptosis is a critical acquired hallmark of cancer, and drug resistance is 
an invariable finding in most clinical cancers.  Therefore, there is a need to identify 
novel small molecules with the ability to bypass the resistance mechanism(s) by 
preferentially activating pathways distinct from classical apoptosis.  In this regard, 
dispelling the long held notion, recent evidence provides substantial support that non-
apoptotic death phenotypes, such as necroptosis and necrosis are not just accidental 
executions, but are regulated in a programmed manner.  Hence, there is a heightened 
interest in studying and unravelling molecular mechanisms/pathways that activate cell 
death that is phenotypically and biochemically different from apoptosis.  
Our laboratory, over the years, has been interested in the identification and 
characterization of novel molecules that elicit potent anti-cancer activity against a 
wide range of human cancer cells.  In this regard, the biological activity of a rare earth 
metal lanthanide, Praesodymium (Pr3+), has been under investigation.  A conjugate of 
Pr3+, Pr-MPO (Pr-mercaptopyridine oxide) was synthesized and its anti-cancer activity 
investigated.  Previous observations suggest that the compound possesses mild PPAR-
γagonist activity, however the precise underlying molecular mechanism of cancer cell 
death remains undefined.  Therefore, the overall objectives of this study were: 
 
1. To decipher and characterize the mode of cell death induced by Pr-MPO in 
cancer cells. 
2. To unravel the underlying molecular mechanism(s) of the anti-cancer activity of 




MATERIALS AND METHODS 
 
1. Cell lines and cell culture 
The human cervical carcinoma Hela cells purchased from American Type Culture 
Collection (ATCC, MD, USA), were cultured in Dulbecco's Modified Eagle Medium 
(DMEM, GE Healthcare Life Science, Utah, USA) supplemented with 1% L-
glutamine, 1% penicillin/streptomycin (Hyclone, ThermoScientific, MA, USA) and 
10% fetal bovin serum (FBS, Hyclone, CA, USA). Hela cell line stably expressing a 
FRET probe fused with a Caspase 3 recognition motif (DEVD-FRET) was a generous 
gift from Dr. Qian Luo (Nanyang Technological University, Singapore). Human 
breast cancer cell lines, MDA-MB-231 and MCF-7 were a purchased from American 
Type Culture Collection (ATCC, Rockville, MD) and maintained in Roswell Park 
Memorial Institute 1640 medium (RPMI, Hyclone, Utah, USA) supplemented with 1% 
L-glutamine, 1% penicillin/streptomycin and 10% FBS. Mouse embryonic fibroblasts 
WT MEF and Atg5 KO MEF cell lines were generously granted by Dr. Noboru 
Mizushima (The University of Tokyo, Graduate School and Faculty of Medicine, 
Tokyo, Japan) and maintained in DMEM medium supplemented with 1% L-
glutamine, 1% penicillin/streptomycin and 10% FBS. Human colorectal carcinoma 
p53 KO HCT116 and Bax/Bak DKO HCT116 cell lines derived from its parental cell 
line HCT116 WT were generously provided by Dr. Bert Vogelstein (The Johns 
Hopkins University School of Medicine, Baltimore, MD) and maintained in 
McCoy5A (Gibco® Invitrogen Corporation, Carlsbad, CA) supplemented with 1% L-
glutamine and 1% penicillin/streptomycin and 10% FBS. All cell lines were 
maintained in a humidified incubator at 37°C with 5% CO2 and propagated according 
to suppliers’ recommendations. 
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2. Reagents and chemicals 
Benzyloxycarbonyl-Val-Ala-Asp (OMe)-fluoromethylketone (Z-VAD-FMK), 
BAPTA-AM were purchased from ALEXIS, (NY, USA). Praesodymium oxide 
(Pr6O11), Cobalt chloride (CoCl2), ammonium persulfate (APS), Necrotatin-1, 3-
Methyladenine (3-MA), Wortmannin, Pepstatin A, Crystal violet, Bromophenol blue, 
Tween 20, EGTA, HEPES, DTT, Glycine, DMF, DMSO, Earle's Balanced Salt 
Solution (EBSS), Bafilomycin A1, Chloriquine, Staurosporin, Rapamycin, Nigericin, 
were purchased from Sigma Aldrich Co (St Louis, MO). Acrylamide/bis-acrylamide 
(30% solution), Coomassie Plus Protein Assay Reagent and Protease Inhibitor 
Cocktail were obtained from Pierce, (IL, USA). 10x PBS, 10x SDS, Tris-HCl buffer 
(pH7.4) were purchased from NUMI Media Preparation Facility (NUS, Singapore). 
Triton X-100 was obtained from USB, (OH, USA). Torin1 was purchased from 
Tocris Bioscience (Bristol, UK).  
 
3. Xenograft animal model 
Tumor inoculation was performed by injecting human prostate cancer cells DU154 
subcutaneously into female nude mice (n=5)/group. Recipient mice were waited till 
tumors reached a mean volume of 50mm3, followed by administration of different 
dosages of Pr-MPO (5, 10, 20mg/kg) by intraperitoneal injection, whilst the control 
group of mice only received injections with DMF solvent. Injections of different 
conditions were given 3 times a week with a total treatment duration of 21days, 
during which tumor volumes and body weight were measured and recorded constantly. 
At the end of the experiment, mice were euthanized and tumors were collected for 




4. Drug treatment 
Synthesized Pr-MPO crystals (synthesized by Dr. Sanjiv Kumar, Department of 
Physiology, National University of Singapore) were dissolved in DMF to obtain a 
5mM stock solution which was protected from light and stable for at least 2 weeks at 
4°C. Stock solution of Necrostain-1, Z-VAD-fmk, Staurosporin, Rapamycin, 
Wortmannin, Bafilomycin A1, Bapta-AM were prepared in DMSO. Torin1, 
Concanamycin, 3-MA, CoCl2, Chloriquine, EGTA, DTT stock solutions were 
prepared in dd H2O2. Nigericin was dissolved in ethanol. Stock solutions of above 
mentioned reagents were kept at -20°C to 4°C for long term storage. In parallel, in all 
experiments unless mentioned otherwise respective solvent controls were used.  
 
5. Transient transfection of plasmids 
The plasmid pEGFP-LC3 containing human microtubule-associated protein 1 light 
chain 3 beta (LC3B) fused with enhanced green fluorescence protein (EGFP) and its 
empty vector  pEGFP-C3 were obtained from Addgene (Plasmid 11546) and Clontech 
(CA, USA), respectively. ptfLC3 is a mammalian expression vector containing the rat 
LC3B gene fused with tandem fluorescent tags of GFP and RFP, which is a generous 
gift from Dr. Noboru Mizushima (The University of Tokyo, Graduate School and 
Faculty of Medicine, Tokyo, Japan). 
Hela cells were optimized to seed at 2.5x106/well (6-well plate) one day prior to 
transfection. When cells had grown to 70% confluence, 2µg plasmid DNA and 5µl of 
Lipofectamine® 2000 Transfection Reagent (Invitrogen™ Life Science, Carlsbad, CA, 
USA) were diluted respectively with 250µl Opti-MEM® Reduced Serum Medium 
(Invitrogen™ Life Science, Carlsbad, CA, USA) for each transfection sample. The 
mixtures were gently re-suspended in the Eppendorf tubes and incubated for 5 min at 
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room temperature. After incubation, the diluted DNA was combined with diluted 
Lipofectamine and mixed well by gentle pipetting. The resultant complex was further 
incubated at room temperature for 20 min before added drop by drop into the wells 
containing cells and medium. Transfected cells were incubated at 37°C for 24 to 48 
hours prior to testing for transgene expression. 
 
6. Small interference RNA gene silencing  
ON-TARGETplus SMARTpool siRNAs (a pool of 4 single siRNAs) targeting human 
Atg5, Atg7, RIP1 and RIP3 as well as scrambled siRNA negative control which were 
not complimentary to any target genes in the organism were purchased from 
Dharmacon Technologies (ThermoFisher Scientific, Lafeyette, CO, USA). 
For silencing of gene expression, siRNA of target gene was introduced into cells with 
Dharmafect1 reagent (Dharmacon) according to the provided manufacture protocol. 
In brief, Hela cells to be transfected were grown to 40% confluence in 6-well plate on 
the day of transfection. For each transfection sample, siRNA was diluted with 250 µl 
of Opti-MEM to attain a final concentration at 50nM; in another tube, 5 µl 
Dharmafect1 was mixed with the equal volume of Opti-MEM. Both mixtures were 
gently mixed and incubated for 5 min at room temperature before proceeding to the 
next step. Similar to plasmid transfection, two mixtures were combined by gentle 
pipetting and the resultant complex with a total volume of 500 µl was incubated for 
20 min at room temperature. Finally, 500 µl siRNA complex was carefully added into 




7. Amplification and purification of plasmids 
To obtain a sufficient amounts of DNA, exogenous genetic material is often 
transformed into bacteria like E. coil to enable a high yield of DNA replication during 
bacteria division. 0.5 µg of DNA plasmid was incubated with 0.1 ml competent E. 
coli (DH5α) in a sterile Eppendorf tube.  These were mixed gently by tapping and 
incubated on ice for 20 min before being subjected to heat shock by placing it in the 
water bath at 42°C for exact 40 seconds and immediately putting the tube back on ice 
for another 2 min. A sudden increase in temperature creates pores in the plasma 
membrane of the bacteria and allows for bait DNA plasmid to enter the bacterial cell. 
250-500 µl LB or super optimal broth (SOC) media (without antibiotic) was added 
into the transformed bacteria and grown in 37°C shaking incubator for 45 min. 50µl 
of the transformants was distributed evenly on one 10 cm LB agar plate containing the 
appropriate antibiotic and incubated the at 37°C overnight. On the following day, a 
single isolated colony was picked and inoculated into a starter culture of 5ml LB broth 
containing selective antibiotic.  The mini culture was incubated in a shaker for 16 
hours at 37°C provided with 5% CO2, after which, 5 ml of mini culture was 
transferred into 250 ml of LB broth containing appropriate antibiotic, one per plasmid,  
to prepare a maxi culture at the same growth condition mentioned above.  Amplified 
bacteria were subsequently subjected to DNA preparation with NucleoBond® Xtra 
DNA purification kit (Macherey-Nagel, Germany), according to the user manual 
instructions.  
Bacteria were harvested from an overnight culture by centrifugation at 6000 x g for 15 
min at 4°C. The bacterial pellet was resuspended in 12 ml of resuspension buffer 
containing RNAase by pipetting the cells up and down. 12 ml of lysis buffer was 
added to the cell suspension solution, mixed gently by inverting the tube 5 times 
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(avoid vortexing the cells vigorously) and incubated at room temperature for 5 min. 
After incubation, cell lysate was immediately mixed with neutralization buffer by 
inverting the tube gently. The off-white flocculate was removed by centrifugation 
before applying the lysate to the equilibrated NucleoBond® Xtra Column Filter. After 
the clear lysate had been filtered, 60 ml washing buffer was applied to the column to 
wash out the remaining lysate to increase the plasmid yield. The DNA plasmid then 
was eluted with 15 ml elution buffer, which was followed by precipitation with 10.5 
ml of room-temperature isopropanol and centrifuged at 15,000 x g for 30 min at 4 °C. 
The supernatant was carefully discarded and the DNA pellet was washed with 70% 
room-temperature ethanol.  This was subjected to centrifugation again at 15,000 x g 
for 10 min at room temperature, before carefully decanting the ethanol without 
disturbing the DNA pellet. The DNA pellet was air dried at room temperature for 5-10 
min and reconstituted with a suitable volume of TE buffer. The yield of DNA plasmid 
was determined by using NanoDrop 1000 Spectrophotometer (Thermo Fischer 
Scientific, Wilmington, DE) at 260 nm. 
 
8. Crystal violet staining  
The cytotoxicity effects of Pr-MPO and various pharmacological reagents or stimuli 
were determined by staining the treated cells with crystal violet and measuring the 
viable cell count by correlating with the absorbance values. Hela cells (1 x 105/ well, 
24 well plate) were seeded in triplicates in a 24 well plate one day prior to drug 
treatment. At the end point of drug treatment, culture medium was carefully discarded 
and cells were washed once with 1x PBS, stained with 200 µl of 0.1% crystal violet 
solution (prepared in 10% methanol) per well and incubated on the shaker for 10 min 
at room temperature. Subsequently, crystal violet solution was disposed into a 
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cytotoxic waste container and cell plate was gently washed with deionized water until 
the water no longer ran dark. The plate was drained by inverting a couple of times on 
a tissue paper. After this, 500 µl of 1% SDS solution (prepared in 1x PBS) was added 
into each well to solubilize the crystal dye.  Absorbance readout was measured with a 
TECAN Sprectrophotometer (Tecan Trading AG, Switzerland) at 570nm. Percentage 
of cell viability was calculated relative to the untreated control cells (presented as 
100%). At least three independent experiment were performed in triplicates to obtain 
statistical significance.  
 
9. Colony forming assay  
At the end point of drug treatment, Hela cells were washed with 1x PBS, trypsinized 
and counted. 10,000 cells of each treated sample were re-plated onto a petri-dish 
containing completed DMEM medium and kept in the incubator to allow colony 
formation over a period of 14 days. The culture medium was changed periodically. 
Cells were stained with crystal violet solution to visualize the colonies; colony 
number and size were determined using the image analysis software Image J 
(http://imagej.nih.gov/ij/) to assess colony forming capabilities of individual sample. 
Only populations containing more than 20 cells were consider as colony units. 
 
10. Analysis of cell viability using propidium iodide  
Necrotic cells are usually defined by lack of integrity of plasma membrane, which can 
be labelled with propidium iodide (PI) staining and measured by flow cytometry. 2.5x 
105 Hela cells were harvested by trypsinization after periodic exposure to drugs. After 
washing twice with cold 1x PBS, cells were stained with 1µM PI solution (prepared in 
cold 1x PBS) and filtered before flow cytometry (CyAn ADP, Beckman Coulter, 
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USA). 10,000 events were collected with the excitation set at 488nm and emission at 
610nm. Data were collected and analysed with WinMDI software (Windows multiple 
document interface for flow cytometry, Beckman Coulter Inc., Sunnyvale, CA). Dot 
plots with a gate drawn around a population of dead cells were adopted to present the 
results.  
 
11. Caspase 3 activity  
Caspase 3 activity assay was performed with a Hela stable cell line constitutively 
expressing caspsase3-specific FRET biosensor (ECFP-DEVD-EYFP) to track the 
undergoing apoptosis event upon drug treatment. Cells were plated onto a 48-well 
plate and incubated with indicated doses of Pr-MPO for 18 hrs. After treatment, cells 
were washed with 1x PBS and subjected to TECAN spectrophotometer for 
fluorescence readout detection. The final relative fluorescence units (RFU) was 
normalized against the protein concentration of samples. The plotted X-fold decrease 
in RFU was inversely proportional to the increase in caspase 3 activity. 
 
12. Protein assay 
Protein concentration of cell lysate was determined by using Coomassie Plus Protein 
Assay Reagent. 1µl of cell lysate from each sample was added into 200µl of reagent 
solution onto a 96-well plate. The absorbance of resultant blue colour was measured 
at 595nm after a short room-temperature incubation. A series of known dilutions of 




13. Western blot analysis 
Whole cell lysate was extracted with 0.1% Triton X-100 cell lysis buffer containing 
protease and phosphatase inhibitors. Protein concentration was quantified and equal 
amount of protein (30-40mg) was prepared with 5x Laemmli loading dye and boiled 
at 100°C for 5min. Denatured protein samples were then subjected to sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with 8, 10, 12 or 15% (v/v) 
of acrylamide resolving gel depending on the molecular weight. Kaleidoscope pre-
stained standards (Bio-Rad, CA, USA) were used to indicate the molecular sizes of 
the resolved protein bands. Subsequently, proteins separated on the gel were 
transferred onto PVDF membrane (BioRad, CA, USA) using the wet transfer method 
at 350mA for 1 hour in an ice bath. Transferred membrane was then blocked with 
blocking buffer for 1 hour on the shaker. Membrane was washed with 1x TBST 3 
times before probing for the target proteins with correspondent primary antibodies at 
4°C overnight. On the following day, membrane was washed 3 times (10 min each 
time) with 1x TBST to avoid non-specific binding with excess primary antibodies and 
probed with appropriate HRP-conjugated secondary antibody solutions for 1 hour at 
room temperature.  For signal visualization, after three washes, membrane was 
incubated with Chemiluminescent Plus Western Blot Enhancing Kit (Merk Millipore, 
Darmstadt, Germany) and developed with X-ray film (Medical X-ray Processor, 
Kodak, NY, USA). 
 
13.1 Western blot buffers 
1% Triton X-100 cell lysis buffer: 50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% v/v 
Triton X-100. Before lysing the cells, the buffer was supplemented with protease and 




Running buffer (Tris-Glycine/SDS): 25mM Tris base, 190mM Glycine, 0.1% SDS 
prepared in Milli-Q H2O. The buffer pH above 8.3 is suitable to use. 
 
Transfer buffer (Tris-Glycine): 25mM Tris base, 192mM Glycine, 10%-20% v/v 
Methanol prepared in Milli-Q H2O. The buffer is prepared freshly each time before 
use as the methanol will break down the glycine over time.  
 
1x TBST buffer: 20mM Tris base, 150mM NaCl, 0.1% v/v Tween 20 prepared in 
dH2O. 
 
Blocking buffer: 5% non-fat milk powder/ Bovine serum albumin (BSA) dissolved in 
1x TBST buffer.  
 
Incubation buffer: 3% non-fat milk powder/ Bovine serum albumin (BSA) dissolved 
in 1x TBST buffer. 
 
Laemmli Loading Buffer 5x (10 ml): Tris-HCL (pH 6.8) 3.1ml (stock: 1M, final 
concentration: 100mM), SDS 1g (10%), glycerol 2ml (20%), β-Mercaptoethanol 
2.5ml (25%), Bromophenol Blue 0.01g (0.1%), topped up to 10ml with 2.4ml of 
dH2O  
 
13.2 Antibodies for western blot analysis  
Primary antibodies specific for PARP, Caspase 3, Bax, LC3B, phospho-mTOR, 
mTOR, phospho-4EBP1, 4EBP1, phospho-S6K, S6K, Atg5 and Atg7 were purchased 
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from Cell Signaling Technology (Danvers, MA); QSTM1/p62, Bcl-2, β-actin and 
GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
HRP-conjugated polyclonal secondary antibodies for anti-rabbit and anti-mouse were 
purchased from Thermo Fischer Scientific (Wilmington, DE, USA). 
 
14. Transmission electron microscopy  
Hela cells were seeded in a 4-well glass bottom chamber and incubated with 5µM Pr-
MPO at indicated time points, followed by fixation for 2 hours in 0.1M Sorensen’s 
Phosphate buffer (Na2HPO4 · 2H2O 35.61g dissolved in 1L dH2O, pH 7.4) containing 
2.5% glutaraldehyde (EM grade) at room temperature. The specimen was washed 
three times with PBS and incubated in Sorensen’s Phosphate buffer overnight at 4°C. 
Specimens were then embedded in plastic, sectioned, and stained with uranyl acetate 
and lead citrate. Thin sections were imaged on a JEOL 1230EX transmission electron 
microscope. Images were acquired by a Gatan ES500W Erlangshen camera with 
1350x 1040 pixels.    
 
15.  Live cells immunofluorescence microscopic analysis  
25,000 per well of HeLa cells were seeded onto a 4-well glass bottom chamber (Lab-
Tek® Chamber Slides, Thermo Scientific Nunc, Wilmington, DE, USA) and 
transfected with green fluorescent protein conjugated LC3B (LC3B-GFP). 24 hours 
post-transfection, cells were treated with 5 µM Pr-MPO for 3 and 6 hours followed by 
three times wash with 1X PBS. Subsequently, cells were fixed with paraformaldehyde 
(4% w/v) for 30 min and permeabilized with 0.5% Triton X-100 solution for 5 min at 
room temperature. To remove the remaining fixative thoroughly, cells were washed 
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with 1X PBS for three times at each interval of 10 min and subjected to FluoView 
FV10i confocal microscopy system (Olympus, Hamburg, Germany). The 
fluorescence of GFP was excited by 488 nm spectral line of the argon-ion laser. 
Fluorescent images were acquired and analysed with Image J software. 
 
16. Live-cell confocal imaging for calcium measurement 
Time-lapse confocal microscopy experiment was performed in collaboration with Dr. 
Marc Fivaz (Duke-NUS, Singapore) using the specific protocol from his group.  
Briefly, microscopy was performed on an inverted Eclipse TE2000-E microscope 
(Nikon, Melville, NY) equipped with a spinning-disk confocal scan head (CSU-10; 
Yokogawa, Tokyo, Japan), an autofocusing system (PFS; Nikon), and a 
temperature/CO2–controlled automated stage. Images were acquired with a Cool 
SNAP HQ2 charge-coupled device camera (Photometrics, Tucson, AZ) driven by 
MetaMorph 7.6 (Molecular Devices, Sunnyvale, CA). For short-term imaging (up to 
10 min) cells were imaged in completed DMEM medium at 37°C supplied with 5% 
CO2. 
 
16.1 Ion indicators  
Fluo4-AM is a cell permeable, green-fluorescent calcium indicator for detecting 
intracellular calcium level. Fluo 4-AM stock solution was prepared with Pluronic F-
127 20% (w/v) solution in DMSO to a concentration of 2mM.  
 
BCECF-AM is a cell permeable, red-fluorescent pH sensor for detecting intracellular 





Calcium Green-1 dextran (Potassium Salt, 10,000 MW) is a cell impermeable, green-
fluorescent calcium indicator. Stock solution was prepared by dissolving it with dH2O 
to a final concentration of 10mg/ml. 
 
Texas Red dextran (Potassium Salt, 7,000 MW) is a cell impermeable, calcium-
insensitive, red fluorescence probe. Texas Red stock solution was prepared with dH2O 
to a final concentration of 5mg/ml. 
Oregon Green dextran, (10,000MW), a hydrophilic green fluorescent probe for 
detecting proton. 10mg/ml stock solution of Oregon green was prepared with dH2O.  
All the ion indicator solutions were kept at -20°C and protected from light exposure.  
 
16.2. Images analysis  
MetaMorph time series images (stacks) were analysed with Image J software. 
Fluorescence intensity within the chosen ROI (the entire cell or several areas within 
the cells) was analysed over the whole series of fluorescent images 
 
17. Intracellular pH (pHi) detection 
pH calibration is a crucial determinant ensuring an accurate and quantitative outcome 
in the detection of intracellular pH. The simplest way to calibrate pH is to employ a 
series of buffers of different pH values, with which a standard pH calibration curve is 
generated. To do so, pH calibration buffer comprising 25mM Na2HPO4 and 25mM 
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KH2PO4 dissolved in distilled water was prepared. Calibration buffer of a series of pH 
values ranging from 6.4, 6.8, 7.2, 7.6, 8.0 were adjusted with HCl or NaOH.  
7,500 Hela cells were seeded onto 48-well plate one day before the measurement of 
intracellular pH. On the day of experiment, cells in triplicates were given 5µM Pr-
MPO and incubated for short durations of 2, 5 and 10min. Treated cells were then 
washed 3 times with 1X HBSS buffer and loaded with fluorescence pH indicator 
solution containing 2µM of BCECF-AM at the room temperature for 30-45min. After 
loaded with BCECF-AM, cells were washed with 1X HBSS buffer thoroughly to 
remove the remnant dye and the emission fluorescence representative of the 
intracellular proton concentration was measured with excitation of 485nm and 
emission of 535nm. Cell samples designated for pH calibration were incubated in the 
buffers of different pH values and followed the same dye loading procedure as 
mentioned above. Before measurement of emission fluorescence, 10µM of nigericin 
was added to equilibrate the intracellular pH with the extracellular buffer pH. 
 
18. Cathepsin L activity assay  
Cathepsin L activity was performed with InnoZyme™ Cathepsin L Activity Kit, 
Fluorogenic which was purchased from Calbiochem. Hela cells incubated with 5µM 
Pr-MPO for various time points (3, 6, 9 h) were trypsinized and lysed with CL lysis 
buffer. All the reagents as indicated in the Reagent Preparation Section included in the 
protocol manual were prepared accordingly. 50µl activation buffer was added to each 
sample performed with a 96-well plate. 50µl of cell lysate, Cathepsin L control 
reaction, Cathepsin L inhibitor working solution 1X and Diluent were added into 
designated wells. 96-well plate was covered with plate sealer and incubated at room 
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temperature for 15min with gentle shaking. After that, 50 µl Substrate Working 
Solution (1X) were added to each well and the plated was incubated at 37°C for 30-45 
min. Emission fluorescence was measured and recorded at an excitation of 360 - 380 






1. The lanthanide conjugate Pr-MPO as a potential new line of anti-cancer 
therapy. 
1.1 Pr-MPO exerts significant tumoricidal activity in human cancer cells.  
Despite a significant progress in understanding the molecular biology of 
carcinogenesis in the past decades, the overall cancer mortality rate has not decreased 
appreciably, due to a multitude of aberrant biological activities which serve as 
impeding factors to cancer therapy. Up to today, conventional cancer treatment widely 
applied in clinics including chemotherapy, immunotherapy as well as radiotherapy, 
primarily aim to activate apoptotic cell death in cancerous cells. However, apoptosis 
deficiency or inefficiency, an acquired hallmark of cancer, provides cancer cells with a 
natural barrier to evade programmed cell death execution thereby promoting survival 
and growth of the tumor. This is further complicated by the ability of cancer cells to 
acquire multiple drug resistance (MDR) after repeated exposure to chemotherapeutic 
agents. The dilemma facing oncologists in treating cancer patients has underscored an 
imperative need for unraveling and understanding alternative cell death modalities as a 
rational basis for the design and development of target specific novel anti-cancer 
compounds. In this regard, our laboratory has endeavoured in the discovery and 
synthesis of promising lead compounds in an attempt to identifying new lines of 
cancer chemotherapeutic agents.  
A lanthanide conjugated compound, praseodymium (2-mercaptopyridine N-oxide) 
(dimethyl sulfoxide) (Pr-MPO), recently developed by our laboratory with a 
molecular weight of 675.62 elicits robust anti-tumor activity against a variety of 





Figure 1. Chemical structure of Pr-MPO. Chemical structure and molecular weight 
of the small molecule compound, praseodymium (2-mercaptopyridine N-oxide) 
(dimethyl sulfoxide) (Pr-MPO). Information of Pr-MPO chemical properties is 
described in Appendices section 1-3. 
 
In an attempt to understand the functional biology of this novel lanthanide rare earth 
metal compound, a variety of human cancer cell lines were screened. Cervical cancer 
cell line Hela, neuroblastoma cell line SHEP-1, and breast cancer cell line MDA-231 
were treated with increasing concentrations of Pr-MPO (1.25 to 10µM) for 18h. Cell 
viability was assessed by crystal violet assay which differentiates the attached 
monolayer cells (viable cells) from non-attached cells (floating cells, dead cells). 
Upon solubilisation, the amount of the crystal violet dye taken up by the attached 
monolayer was proportional to the number of viable cells. Result revealed that Pr-
MPO induced a pronounced loss of cell viability in all three cancer cell lines despite 
their different origins as shown in Figure 2A. Compared to untreated controls, Pr-
MPO exerted a dose-dependent reduction in cell viability with an approximate IC50 of 
5µM, which was selected as a working concentration in all subsequent experiments 
unless otherwise mentioned.  
Pr-MPO molecular weight 675.62 
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To corroborate the result obtained from crystal violet assay, a colony forming assay as 
described in Materials and Methods was performed to further investigate the progeny-
reproducing capability in cells upon exposure to Pr-MPO treatment (Figure 2C). To 
that end, 18h incubation with 5µM Pr-MPO drastically suppressed tumor colony 
formation, compared to untreated controls. As colony forming assay enables to assess 
cancer cell clonogenic capability after exposure to chemical compounds or genetic 
modulators, these results are indicative of a compromise in the reproductive viability 
of cancer cells by Pr-MPO treatment. Meanwhile, cell death morphology was also 
documented with light microscopy at the end of Pr-MPO treatment (Figure 2B). 
Microscopic appearance of dying cells showed a shrinking morphology with mottled-
looking nuclei and increasingly translucent cytoplasm, filled with a number of 
intracellular vacuoles. However, canonical apoptosis morphological features such as 
plasma membrane blebbing and membrane-bounded apoptotic bodies were barely 
observed, which provided testimony that the phenotype of cell death triggered by Pr-
























Figure 2. Pr-MPO induces significant cell viability loss in a variety of human 
cancer cell lines. (A). Turmoricidal activity of Pr-MPO was extensively tested with a 
few human cancer cell lines; Hela, MDA-231 and SHEP-1 were incubated with 
indicated concentrations of Pr-MPO for 18h. Cell viability was determined by crystal 
violet assay and expressed as % of untreated control. Data are shown as means ± 
s.e.m of three independent experiments. (B). Phase contrast images of Hela, MDA-
231, SHEP-1 cell morphology were taken after 18h treatment with or without Pr-
MPO 5µM. (C). Colony forming assay was performed with cells after 18h exposure to 
5µM Pr-MPO. Treated cells were subsequently trypsinized and re-seeded onto 
100mm petri dishes. Cell clonogenic ability was assessed after 14 days incubation.  
 
 
1.2 Pr-MPO elicited robust cell death response in both apoptosis resistant and 
deficient cancer cells. 
Stimulated by the evidence that Pr-MPO induced cell death was possibly non-
apoptotic, we next sought to test whether Pr-MPO retained its ability to target cancer 
cells that had been rendered resistant to or deficient in apoptosis signaling. Firstly, a 
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set of isogenic HCT116 human colon carcinoma cell lines containing targeted 
disruption of pro-apoptotic BH3-only genes Bax and Bak (Bax/Bak DKO) or tumor 
suppressor gene p53 (P53 null) were employed to investigate the antitumor activity of 
Pr-MPO in cells with different sensitivities to classical apoptosis stimuli. To evaluate 
the effect of apoptosis inducers on cell viability of WT, Bax/Bak DKO and p53 KO 
HCT116 cells, cells were incubated with the widely used chemotherapeutic agents, 5- 
Fluorouracil (5-FU) and Doxorubicin (Dox), at indicated concentrations for 48h. As 
shown in Figure 3A and B, WT HCT116 cells underwent rapid apoptotic cell death in 
a dose-responsive manner upon exposure to 5-FU and Dox. Unlike the parental 
counterpart, both DKO and p53 KO cell lines elicited a marked resistance to 5-FU 
mediated apoptosis with a nominal percentage of cell death (~10%-20% compared to 
50%-80% in WT cells). Similar result was also obtained in Bax/Bak DKO cells with 
Dox treatment in which the cytotoxicity was greatly suppressed and cell viability was 
concomitantly increased three-fold in comparison to its counterparts. These data are 
consistent with previous studies demonstrating that HCT116 Bax/Bak DKO and p53 
KO cells were resistant to apoptotic cell demise in the absence of pivotal apoptotic 
machineries (Yoon, Lee et al. 2009, Wang and Youle 2012). To explore the cytotoxic 
effect of Pr-MPO on cancer cells with apoptosis-deficient or -inefficient background, 
various doses of Pr-MPO were administrated to HCT116 WT, Bax/Bak DKO and 
p53KO cells for 18h incubation. Crystal violet assay was performed to estimate the 
cell viability as previously described. As illustrated in Figure 3C and D, stable 
knockdown of Bax, Bak and p53 genes had virtually no effect on the response of 
HCT116 cells to Pr-MPO. Both knockout cell lines exhibited sensitivity to Pr-MPO 
that was comparable to the WT cells.  
 58 
 
To further confirm this, similar experiment was carried out with cancer cells that had 
acquired the ability to evade programmed cell death after repeated exposure to 
chemotherapeutic drugs and eventually developed multidrug resistant phenotype. In 
this regard, a cisplatin resistant clone (3CG) derived from the non-small cell lung 
carcinoma cell line A549 by repeatedly exposed to low dose of cisplatin (5µM) for 6 
months (generous gift from Dr. Catherine Brenner, University of Paris Sud, Chatenay 
Malabry, France) was tested. Before studying the response of these cell lines to Pr-
MPO, I set out to verify the resistant phenotype by comparing the respective 
sensitivity of parental A549 and the resistant 3CG clone to increasing concentrations 
of cisplatin (25, 50 and 75µM).  Following treatment for 48h, cell viability was 
determined by crystal violet assay. Results showed that, as expected 3CG cells 
displayed a significantly better survival percentage than the parent A549 cells (Figure 
3E). Intriguingly, despite their disparate response to cisplatin, the two cell lines (A549 









Figure 3. PrMPO exerts potent antitumor effect in apoptotic deficient and 
resistant cells. HCT116 colorectal cancer cell lines (WT, Bax/Bak DKO) (A), 
HCT116 p53 WT, HCT116 p53 KO (B), non-small lung cancer cells A549 and 
cisplatin resistant clone 3CG derived from A549 parental cells (C), were treated with 
indicated concentrations of different apoptosis stimuli: 5FU(175, 350µM), 
doxorubicin(2.5, 5µM) for 24h or cisplatin (12.5-50µM) for  48h. Cytotoxicity of Pr-
MPO was also tested in these three scenarios as mentioned above. Various doses of 
Pr-MPO ranging from 1.25-10µM were incubated with cells for 18h before crystal 
violet assay. Cell viability was determined and expressed as % of untreated control. 





1.3 Pr-MPO was efficacious in xenograft murine model 
Tumoricidal activity of Pr-MPO was demonstrated in a variety of cancer cell 
including cells bearing mutations or defects in apoptosis signaling. To provide 
translational relevance for the in vitro data, the anti-cancer activity was also assessed 
in vivo.  A xenograft mouse model was generated as described previously in the 
Materials and Method section.  The treatment regimen is shown in Figure 4A.  At the 
end of the experiment, a significant difference was observed in tumor volumes 
between the control and treated mice groups as shown in Figure 4B and C. Three 
groups of mice treated with increasing dosages of Pr-MPO ranging from 5 to 20 
mg/kg all exhibited an order of magnitude reduction in tumor volumes (Figure 4B).  
Of note, Pr-MPO at minimum dosage of 5mg/kg is sufficient and potent to induce a 
virtual complete inhibition in tumor growth. In addition, recipient animals didn’t 
show any noticeable side effect during the course of Pr-MPO treatment, for instance, 
no obvious loss of body weight and reduction in diet and fluid intake.  
Collectively, both in vitro and in vivo experimental data provide evidence that Pr-
MPO exerts profound anticancer activity not merely in generic cancer cells, but more 
notably in cancer cells with defective and/or deficient apoptotic signaling as well as in 
cells exhibiting a MDR phenotype. These data also provide a clue to an alternative 








Figure 4. Pr-MPO exhibits profound anti-tumor effect in a xenograft mouse 
model. (A) Diagram of animal experiment design. Nude mice (female, n=5 each 
treatment group) were initially injected with prostate cancer cells DU145 
subcutaneously. When the tumor sizes reached 50mm3, various dosages of Pr-MPO 
ranging from 5 to 20 mg/kg were injected intra-peritoneally to thrice weekly over a 
total period of 21 days. (B) At the end of the experiment, mice were euthanized and 
tumor specimens were collected. (C) Volumes of vehicle and Pr-MPO-treated tumors 
were measured and recorded at designated days. 
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2. Pr-MPO induced cell death without apoptosis hallmarks.  
Based on the morphological hallmarks and the fact that the drug induced death in 
apoptosis resistant cells, the primary objective of this study was to understand the 
underlying molecular mechanism of Pr-MPO-induced cancer cell death. Human 
cervical cancer cell line Hela was employed as the main experimental model 
throughout the whole study. Treated Hela cells were loaded with propidium iodide (PI) 
and analysed by flow cytometry to identify cells whose membranes permeability had 
been compromised and thus had readily taken up PI.  Result revealed that Pr-MPO 
exerted potent anti-tumor activity against Hela cells in a dose-dependent manner with 
an approximate IC50 of 5µM (Figure 5), which was in line with the previous data 
obtained by crystal violet assay. 
 
Figure 5. Pr-MPO exerts potent anti-tumor activity against Hela cells. Hela cells 
were treated with indicated concentrations of Pr-MPO for 24h. The extent of cell 
death was determined with propidium iodide (PI) staining by using flow cytometry 
analysis. The axis represents the percentage of PI-stained cells (cell death) expressed 
as % of untreated control. Data are shown as means ± s.e.m of three independent 




In order to further explore whether there was any evidence of apoptosis in this model, 
apoptosis hallmarks were detected by a series of experiments. To do so, I first 
investigated if cell death induced by Pr-MPO showed any involvement of caspase 
proteases and whether this cell death could be inhibited by the pan-caspase inhibitor 
zVAD-fmk. Results obtained by Western Blot analyses performed on lysates of cells 
following exposure to Pr-MPO (at indicated time points) revealed no evidence of 
caspase activation, such as proteolysis of pro-caspase 3, which acts as the key 
executioner in controlling programmed cellular demise. A time-dependent reduction 
in pro-caspase 3 protein level was observed without a detectable processing/cleavage 
of caspase 3, indicating that cell death was not apoptotic in nature; the loss of cell 
membrane integrity resulted in the release of pro-caspase 3 into the cell medium 
(Krysko, Vanden Berghe et al. 2008). Consistent with this, proteolysis of caspase-3 
substrate PARP was rather weak as well, given that massive cell death occurred at the 
end of the treatment. Additionally, expressions of both the pro-apoptotic and anti-
apoptotic BH-3 only proteins were not regulated by Pr-MPO treatment throughout the 
course of the treatment (Figure 6A).  
To verify our western blot results, caspase-3 activity assessment was carried out in 
Hela stable cell line expressing a caspase-3 FRET biosensor. This FRET reporter is 
designed specifically to detect caspase-3 activity, which consists of a fluorescent 
donor (cyan fluorescent protein, CFP) and an acceptor (yellow fluorescent protein, 
YFP). The linker sequence contains caspase-3 recognition and cleavage residue, 
DEVD. Caspase-3 activity is directly reflected by the emission fluorescence intensity 
between YFP and CFP (535nm/480nm). Activation of caspase-3 leads to the cleavage 
of the linker, thus, effectively bringing down the fluorescence intensity ratio below 1, 
whereas in the control condition where caspase 3 remains inactive, the FRET readout 
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is supposed to stay above 2. As shown in Figure 6 B, a temporal dynamics of caspase-
3 activity in response to Pr-MPO treatment was investigated. Staurosporine, used as a 
positive control, induced robust caspase-3 activation at 1.5µM, whereas, the negative 
control H2O2, at a necrotic dose of 1mM, had the opposite effect. Fluorescence 
intensity ratio (535nm/480nm) was dramatically decreased from 2.5 down to 1 in 
staurosporine treated cells in a time-responsive manner, however, as expected, there 
was no noticeable effect displayed by 1mM H2O2 treatment. Similar to what we 
observed in H2O2 group, caspase-3 activation by Pr-MPO was not evidenced at two 
tested concentrations, indicating that Pr-MPO induced cell death did not engage the 
executioner caspase-3. Furthermore, pre-incubation of cells with two effective doses 
of pan-caspase inhibitor Z-VAD-FMK (25 and 50µM) failed to block Pr-MPO 
induced cell death, while successfully prevented staurosporine triggered apoptotic cell 
death. Altogether, these data strongly suggest that Pr-MPO-induced cell death does 




Figure 6. Pr-MPO induces non-apoptotic cell death. (A). Hela cells incubated with 
Pr-MPO for indicated durations were harvested and lysed. Cell lysate was subjected 
to western blot analysis and apoptosis markers were assessed. (B). Caspase 3 activity 
was achieved by measuring the extent of fluorescence resonance energy transfer 
within a recombinant substrate stably expressed in Hela cells containing cyan 
fluorescent protein (CFP) linked by a short peptide possessing the caspase-3 cleavage 
sequence, DEVD, to yellow fluorescent protein (YFP; i.e. CFP-DEVD-YFP). The 
bars represent means + s.e.m from three independent experiments. *, p < 0.05 and **, 
p < 0.01 compared with shRNA negative control cells receiving the same treatment. 
(C) HeLa cells were pre-incubated with the pan-caspase inhibitor Z-VAD-FMK (25 or 
50 µM) for 2h followed by Pr-MPO 5µM for 18h. Apoptotic inducer staurosporine 
was used as a positive control at a concentration of 250nM. 
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3. Pr-MPO induced robust autophagy activation in human cancer cells. 
3.1 Pr-MPO triggered mTOR-dependent autophagy event 
Intrigued by the findings that Pr-MPO did not induce features consistent with 
apoptosis, I set out to investigate whether non-apoptotic cell death such as autophagy, 
necrosis, or necro-apoptosis could account for the anti-tumor activity of Pr-MPO. One 
feature continuously appeared while analysing the morphology of cells following Pr-
MPO treatment was the presence of multiple cellular vacuoles in cytoplasma, which 
was in line with an observation that had been described by a previous study done in 
the lab.  
Therefore, I first asked if Pr-MPO could be inducing cell death with autophagic 
characteristics. Intent on answering that question, I first looked at the most commonly 
used biochemical marker of autophagy, the conversion of LC3I to LC3-II (Mizushima, 
Yoshimori et al. 2010). The amount of LC3-II is closely correlated with the number of 
autophagosomes, serving as a good indicator of autophagosome formation. Indeed, 
immunoblotting analyses revealed that 5µM Pr-MPO treatment resulted in a 
significant formation of autophagy marker LC3-II as early as 3h of incubation, 
concomitantly with a decrease in expression of the autophagy flux marker p62 
(SQSTM1/sequestosome 1) (Figure 7A). The autophagy inducting effect of Pr-MPO 
was compared with several conventional autophagy inducers, including amino acid 
starvation in EBSS buffer, rapamycin and torin1, all of which have been widely used 
to induce autophagy through inhibition of mTOR signaling pathway. In line with 
these positive autophagy modulators, Pr-MPO induced autophagy was also observed 
to involve inhibiting mTOR activity; both the mTOR substrates, 4E-BP1 and S6K, 
were significantly dephosphorylated upon Pr-MPO treatment. Rapamycin acts a 
potent allosteric mTORC1 inhibitor only partially block mTOR downstream pathway, 
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whereas Torin1 is highly potent and selective ATP-competitive mTOR inhibitor that 
directly inhibits both complexes of mTOR (Thoreen, Kang et al. 2009). Results of 
western blot analysis by using these two inhibitors had indicated that the inhibitory 
effect of rapamycin was exerted on only one mTOR substrate, S6K, thus leaving 4E-
BP1 unaffected, whereas Torin1 exhibited a full competency in blocking downstream 
activation of mTOR. Furthermore, the fact that Pr-MPO seem to inhibit both 
substrates indicates a mechanism similar to Torin 1 but distinct from rapamycin.   
Moreover, to visualize autophagosome formation, LC3 fused green fluorescent 
protein construct (GFP-LC3) was introduced into Hela cells 24h prior to Pr-MPO 
treatment. The fluorescent puncta, representative of autophagosome formation, were 
monitored and quantified by confocal microscopy (Figure 7 B). In control cells 
without autophagy induction, GFP-LC3 was diffusely distributed in the cytoplasm 
and no punctate dots were evidenced. However, cells subjected to Pr-MPO treatment 
displayed a marked increase in the LC3 puncta, indicating an increase in autophagy 
induction. These data suggest that the autophagy inducing activity of Pr-MPO might 













Figure 7. Pr-MPO induces mTOR-dependent autophagy event. (A). Hela cells 
were treated with Pr-MPO 5µM for indicated times before cells were harvested and 
lysed. Pr-MPO induced autophagy in Hela cells was compared with conventional 
autophagy inducers, 0.1µM Torin1, 0.5µM Rapamycin and amino acid (AA) 
depletion by incubating cells in EBSS buffer at indicated times. Cell lysates were 
collected and subjected to western blot to measure the levels of autophagy markers 
and mTOR substrates. (B). Hela cells were transfected with GFP-empty vector or 
GFP-LC3 vector for 24h followed by 3h of exposure to 5µM Pr-MPO. 
Autophagosome formation, represented by fluorescent GFP-LC3 puncta, was 
observed under a fluorescence microscope.  
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3.2 Pharmacological inhibitors and genetic silencing of ATG genes abrogated 
autophagosome formation by Pr-MPO 
Recent reports have suggested that LC3 mRNA is induced during autophagy 
induction (Nara, Mizushima et al. 2002, Kanzawa, Germano et al. 2004). Therefore to 
confirm that autophagy induction by Pr-MPO was responsible for elevated LC3-II 
expression and not its transcriptional regulation, either the pharmacological inhibitor 
3-Methyladenine (3-MA) or genetic manipulation of ATG genes by siRNAs was 
exploited to inhibit autophagy. 3-MA is one of the most commonly used 
pharmacological inhibitors of autophagy and works by inhibiting class III PI3 kinase 
activity. Successful inhibition of autophagy was achieved with 2h pre-incubation of 3-
MA before Pr-MPO treatment, as evidenced by a profound decrease of LC3-II levels 
in Pr-MPO-exposed Hela cells (Figure 8A).  Assuming that LC3II elevation mediated 
by Pr-MPO was indeed due to an autophagy event rather than LC3 transcriptional or 
translational regulation, the absence of either Atg5 or Atg7, the most essential ATG 
genes in autophagosome formation, would lead to autophagy deficiency. This was 
asserted with an effective reduction of LC3-II level in cells transfected with siRNAs 
targeting Atg5 and Atg7.  The efficiency of gene silencing upon siRNA transfection 
was validated by Western blotting, which clearly showed effective gene knockdown 
(Figure 8B). 
Not only did we confirm the suppression of autophagy with the above mentioned 
approaches, we also verified the significant inhibition of autophagy by using mouse 
embryonic fibroblast cell lines lacking the autophagy gene Atg5 (MEFs Atg KO). 
MEFs cells have been extensively employed in autophagy study and reported to 
exhibit a strong susceptibility to autophagy modulators (Mizushima, Yoshimori et al. 
2010), hence, a series of low doses of Pr-MPO (0.25-2.5µM) were delivered to MEFs 
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Atg5 KO and WT cells for 3h and 6h incubation. Cell lysate were collected at the end 
of the treatment and subjected to western blot analyses. As seen from Figure 8C, 
converted LC3II started to appear in WT cells during the first 3h of incubation with 
Pr-MPO ranging from 0.5 to 2.5 µM. The highest LC3II protein level was achieved at 
latter time point with 1µM Pr-MPO in converse correlation with a reduction in LC3I 
expression. In contrast, by given the same treatment conditions, no noticeable LC3II 
signal was detected in MEF Atg5 KO cells (Figure 8D). These lines of evidence 
consistently demonstrated the existence of autophagy in Pr-MPO treated human 
cancer cells, which was prohibited by either blocking autophagy signaling or 












Figure 8. Pr-MPO-triggered autophagy event is blocked by PI3K inhibitor and 
ATG gene silencing. (A) Hela cells were pre-incubated with autophagy inhibitor 3-
MA at 5mM for 2h, or transfected with siRNA against Atg5 and Atg7 genes for 24h 
(B), followed by 3h or 6h Pr-MPO treatment, protein level of LC3II was assessed by 
western blot. (C). Mouse embryonic fibroblasts (MEFs) cells together with (D) MEFs 
Atg5 knockout cells were tested with indicated concentrations of Pr-MPO ranging 
from 0.25 to 2.5 µM and incubated for 3h or 6h. Cell lysates were collected and 









4. Pr-MPO exerted potent cell viability loss in human cancer cells was not 
autophagy-dependent 
4.1 Pr-MPO induced an increase in autophagosome formation without causing a 
functional autophagic flux 
Encouraged by the compelling evidence demonstrating robust autophagy induction in 
Pr-MPO treated human cancer cells, we asked if autophagy was accountable for the 
cell viability loss triggered by this novel compound. Owing to a body of observations 
on excessive levels of autophagy in association with various forms of cell death 
(Pattingre, Tassa et al. 2005, Maiuri, Zalckvar et al. 2007, Scott, Juhasz et al. 2007), 
the term of autophagy cell death was initially generated to describe cell death 
associated with autophagy. However, this new definition of cell death considered as a 
misnomer had undergone a considerable debate among scientists as its role on cell 
death was rather elusive and circumstantial. In recent years, with the growth in 
research on autophagy and cell death, it is now well accepted that autophagy exerts 
cell cytotoxicity and accounts for cell demise in eukaryotes (Kroemer and Levine 
2008). Thus, a new definition of autophagic cell death has been reintroduced to 
describe a cell death that is suppressed by inhibition of autophagy pathway, which 
happens only if the process meets the following criteria: (1) cell death occurs without 
the involvement of apoptosis machineries; (2) There is an increase in functional 
autophagy flux, not merely in autophagy biomarker LC3II; (3) Genetic intervention 
and pharmacological inhibition of autophagy rescue majority of cell death (Shen and 
Codogno 2014). These more stringent criteria has provided a dogma for researchers to 
distinguish autophagy cell death from autophagy per se or from cell death with 
autophagy as a bystander. Therefore, in our study, whether autophagy was 
mechanistically contributing to the cell death or merely accompanied with an 
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accumulation of autophagic vacuoles, several experiments were carried out to address 
this essential question. 
In positive accordance with the first criterion, results obtained in our earlier studies 
have unequivocally ascertained the fact that Pr-MPO triggered cell death was not a 
consequence of apoptosis (Figure 6). In addition, the evidence that Pr-MPO triggered 
a rigorous autophagy response in cancer cells, exemplified by the substantial elevation 
in LC3II/Atg8 compared to canonical autophagy modulators, could be the result of 
either an increase in autophagy induction or blockade in autophagy flux, hence, 
increase, rather than decrease Atg8/LC3II.  
The term “autophagy flux” is generated to denote the dynamic process of 
autophagosome formation, autolysosome maturation, autophagosome degradation and 
its substrates clearance in lysosomes (Bjorkoy, Lamark et al. 2009). Although the 
quantification of autophagosomes and autolysosomes by imaging tools could help to 
identify the status of autophagy dynamics, it can’t provide a reliable indication of 
autophagic substrates degradation in lysosomes. Therefore, a more experimentally 
straightforward approach for monitoring autophagic flux is to assess the degraded 
autophagic cargos inside the lysosomes by LC3II/Atg8 turnover assay using western 
blot analysis in the presence or absence of lysosomal degradation inhibitors, such as 
chloroquine, bafilomycin A1 (Bal-A1), pepstatin A, Ed64, etc. (Mizushima, 
Yoshimori et al. 2010). If autophagy flux is truly occurring, an increased level of 
LC3II/Atg8 should be detected in the presence of a lysosomal degradation inhibitor as 
the transportation of autophagosomes to lysosome pathway is blocked and the 
increased extent of LC3II/Atg8 represents the amount of autophagosomes delivered to 
lysosomes for degradation. Based on this, an inhibitor of vacuolar type H+-ATPase, 
bafilomycin A1, which prevents LC3-II turnover by inhibiting fusion between 
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autophagosomes and lysosomes, was pre-added to cells for 2h followed by Pr-MPO 
treatment for 3h or 6h. As shown in Figure 9A, Torin1, applied as a positive control, 
significantly increased LC-3II levels in the presence of lysosome inhibitor. It is 
noteworthy that, even though some basal increase in LC3II levels was observed with 
bafilomycin treatment alone, the difference was obviously augmented in combination 
with Torin1. In contrast, although Pr-MPO induced LC3II was slightly augmented in 
the presence of bafilomycin, it was comparable with the extent of increase in 
bafilomycin alone, implying an incomplete autophagy flux induced by Pr-MPO. To 
confirm this, cells were pre-incubated with another lysosomotropic agent chloroquine 
which leads to inhibition of both autophagosome fusion and degradation by intra-
lysosomal pH neutralization.  Pre-incubated cells were followed by incubation with 
5 µM Pr-MPO at indicated times. Western blot results revealed a reproducible 
increase in LC3II/Atg8 protein level in response to Pr-MPO treatment, as shown in 
Figure 9B. Similarly, Pr-MPO induced LC3II/Atg8 showed a substantial increase in 
the presence of cholorquine, however, it was just comparable with the LC3II basal 
level increase in chloroquine alone. Observations obtained in abovementioned 
conditions suggest an impaired autophagosome maturation and lysosome fusion in 
spite of the significant accumulation of autophagosomes elicited by Pr-MPO.  
Of note, p62/ SQSTM1, ubiquitin- and LC3-binding protein, binds directly to LC3 via 
a specific sequence motif and serves to shuttle autophagy machineries to ubiquitin 
proteins to enable its degradation in lysosomes. Researchers regarded p62 as a 
promising indicator to study autophagy flux in favour of the inverse correlation of 
total cellular protein level of p62 and autophgic activity (Bjorkoy, Lamark et al. 2005). 
Nevertheless, it is yet not clear whether p62 degradation is solely through autophagy 
flux or alternatively through ubiquitin-proteasome pathway. Additionally, p62 has 
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been reported to be an oxidative stress inducible gene regulated by Nrf2 with 
increases at both protein and mRNA levels (Ishii, Yanagawa et al. 1997); inhibition of 
proteasomal activity also suggested an induction of p62 (Ishii, Yanagawa et al. 1997, 
Thompson, Harris et al. 2003). These alternative regulatory means may confound the 













Figure 9.  Effect of Pr-MPO on LC3 turnover assay by western blot analysis (A). 
Hela cells were pre-incubated with 10nM Bafilomycin A1 for 2h before 3h or 6h 
treatment with Pr-MPO at 5µM. Torin1 (100nM, 3h) served as a positive control of 
autophgy flux induction. Cells were harvested for western blot analysis of LC3II and 
p62 levels.  (B). Cells pre-treated with 20µM chloroquine for 2h followed by 5µM Pr-





Given these potential limitations and experimental pitfalls, it is recommended to 
evaluate autophagy flux in combination with other independent experiments. The use 
of a tandem fluorescence tagged LC3 probe (mRFP-EGFP-LC3) has been proposed as 
another useful assay for visualizing autophagy flux (Kimura, Noda et al. 2007). The 
principle underlying this assay is based on the differential quenching kinetics of 
fluorescence proteins once autophagosomes are fused into autolysosomes. It has been 
documented that EGFP emits weak signals in acidic environment, such as late 
endosomes and lysosomes, whereas RFP exhibits better stability in low pH milieu. 
Hence, signal of EGFP but not RFP will diminish when mRFP-EGFP-LC3 expressing 
autophagosomes fuse with lysosomes. In such an event, the autophagosome-lysosome 
fused organelle will present more reddish puncta without the contribution of EGFP; 
by contrast, if the fusion process is dysfunctional, the autophagosomes carrying 
mRFP-EGFP-LC3 vector will emit stable signals of both EGFP and RFP, in this case, 
an integrated yellow signal can be visualized. Hela cells were seeded onto a glass 
bottom chamber and transiently transfected with tandem RFP-EGFP fluorescent-
tagged LC3 (tfLC3) for 24h in order to attain good transfection efficiency. 
Transfected cells were subsequently treated with Pr-MPO for 3h and subjected to 
confocal microscopy to monitor live cell autophagy flux. Both fluorescent images and 
phase contrast images were acquired throughout the whole experiment. By using this 
vector, mRFp-EGFP-LC3 expressing cells without Pr-MPO treatment displayed a 
uniformly diffused LC3-asosociated EGFP and RFP signals; autophagic puncta 
formation was induced after 3h incubation of 5µM Pr-MPO, revealed in both 
fluorescent channels. In merged channel, some puncta appeared in red representing 
autolysosome organelles, whereas the majority of punctate aggregates still remained 
in yellow (Figure 10). This pattern of fluorescent puncta implying an incomplete 
 78 
 
autophagy flux occurred in Pr-MPO treated cells. Phase contrast images were 
captured to indicate cell conditions undergoing drug treatment and real-time imaging. 
 
Figure 10. Detection of autophagosome maturation by tfLC3 using live-cell 
imaging. Hela cells at 24h post-transfection with tfLC3 construct (EGFP-RFP-LC3) 
were treated with or without Pr-MPO 5µM for 3h. Fluorescent images of LC3 
punctuation/aggregation was acquired under each channel, and the corresponding 
phase contrast images. 
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4.2 Autophagy was not the mediator of Pr-MPO triggered cell demise 
Despite the observation of increased autophagy prior to the occurrence of Pr-MPO-
mediated cell death, the question still remains as to whether autophagy is the mediator 
of Pr-MPO induced cell death, an accomplice or just an innocent bystander. To clarify 
this, cell viability experiment was repeated with cells that were pre-incubated with 
autophagy inhibitors 5mM 3-MA or 50nM wortmannin or transfected with siRNAs 
for Atg5 and Atg7 before Pr-PMO administration. Post-treated cells were then 
subjected to PI staining and dead cell percentage was scored by FACS analysis. 
Successful inhibition of autophagy was achieved by 2h incubation of pharmacological 
inhibitors and 24h transfection with siRNAs, as evidenced by western blot results 
obtained in earlier studies. Data from FACS analysis clearly showed that attenuation 
of autophagy initiation and genetic interventions of autophagosome machineries failed 
to rescue Pr-MPO-induced cell death (Figure 11A and B). SiRNA transfection had 
rendered cells more susceptible to cell death stimuli compared to cells incubated with 
pharmacological inhibitors. Thus, a much higher cell death incidence was observed in 
siRNA transfected cell group: ~10% of cell death at basal level and ~75% of cell 
death upon Pr-MPO treatment.  
Cell death morphology were also recorded and compared with phase contrast 
microscopy (Figure 11 C). 3-MA or wortmannin alone at respective concentrations 
did not cause apparent cell damage; in combination with Pr-MPO, cell morphology 
retained lethal and was comparable to what was observed in Pr-MPO single-treated 
cells, without noticeable cell death rescue.  The FACS data were verified in a different 
type of human cancer cell line, MDA-231 breast cancer cells, using the crystal violet 
viability assay (seen in Figure 11 D). 
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Based on the aforementioned observation, although Pr-MPO induced an active 
autophagy event in the cells, the lack of convincing evidence on autophagic flux and 
cell death association led us to conclude that Pr-MPO-conducted cell death was NOT 

























Figure 11. Pharmacological and genetic interventions of autophagy could not 
inhibit Pr-MPO induced cell death.  (A) Hela cells were pre-treated with autophagy 
inhibitors 3-MA or wortmanin at the concentration of 5mM and 50nM respectively 2h 
before 5µM Pr-MPO incubation for 18h; (B) Cells were transiently introduced with 
50nM of siRNAs targeting Atg5 and Atg7 or scrambled controls for 48h, followed by 
5µM Pr-MPO exposure for 18h. Cells were subsequently labelled with PI and cell 
death extent was measured using FACS analysis. (C) Pr-MPO treated cell 
morphology in the presence or absence of autophagy inhibitors was documented using 
transmitted light microscopy. (D) Cell viability of Pr-MPO-treated cells in 
combination with autophagy inhibitors was repeated in human breast cancer MDA-
231 cells with the abovementioned experimental conditions. Cell viability loss was 












4.3 Transmission electron microscopy suggested a necrotic cell death 
morphology  
Hitherto our results had shown that neither canonical apoptosis nor prevailing 
autophagic cell death accounted for Pr-MPO mediated cell death, which had accorded 
us with an intricate question on what exact mechanism was involved in regulating 
cancer cell death by Pr-MPO. According to Galluzzi et al., cell death modalities are 
known to be perpetrated through a variety of mechanisms accompanied with distinct 
morphological features, based on which cell death can be classified into four different 
types: apoptosis, autophagy, necrosis and mitotic catastrophe (Galluzzi, Maiuri et al. 
2007). Our initial findings with the emergence of massive intracellular vacuoles, 
translucent cytosol and cellular swelling in response to Pr-MPO inspired us to relook 
at those morphological traits in an attempt to discriminate the cell death phenotype.  
Transmitted electron microscopy, due to its high resolution, is still considered as the 
“gold standard” to provide a more detailed characterization of cell death, allowing 
morphological analysis of intracellular compartments, such as nucleus alteration, 
mitochondria swelling, loss of cell membrane integrity, etc. For this reason, 
ultrastructure characterization of cell death was carried out with transmitted electron 
microscopy upon incubation for different durations with Pr-MPO. 
2x105 cells/well were seeded onto a 4-well Tek-Lab glass-bottomed chamber for 24h 
prior to Pr-MPO treatment at indicated time points as described in the figure legend. 
After treatment, cell monolayer attached on the glass chamber were fixed with 0.1M 
Sorensen’s Phosphate buffer for 2h; specimens were subsequently embedded, 
sectioned and stained as described in the Material and Methods. Serving as 
morphological indicators for cell death identification, ultrastructure modifications of 
cell membrane integrity, nucleus chromatin condensation, organelle dilation and 
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intracellular vacuole formation were compared before and after Pr-MPO treatment. 
Figure 12 A, B, C, shows a representative example of a healthy cell morphology of 
vehicle treated cells with intact plasma membrane and smoothly outlined nucleus 
filled with chromatin in a form of heterochromatin. Mitochondria, the pivotal 
organelle in regulation of cell death, were well preserved with a tubular cristae 
ultrastructure. In stark comparison to the normal counterpart, organelle morphology 
was significantly affected in Pr-MPO treated samples (Figure 12. D, E, F). Cells 
incubated with Pr-MPO for 6h experienced striking morphological alterations. 
Nuclear chromatin was partially condensed and aggregated into clumps (arrow head) 
with ill-defined edges; mitochondria dilated and matrix volume swelled (arrow head); 
massive cellular vacuoles accumulated in the cytoplasm filled with cellular remnants, 
which implied an imbalance in osmotic pressure. Organelle and cell swelling is the 
most remarkable morphological features of necrosis that culminates in the rupture of 
the plasma membrane. Based upon morphological and biochemical results, it appears 
that the death inducing activity of Pr-MPO involves pathways that favour the 
















Figure 12. Transmitted electron microscopy analysis of Pr-MPO-mediated cell 
death. (A-C). Cells were cultured in the absence of Pr-MPO; or in the presence of 
5µM Pr-MPO for 6h (D-F). Morphological modifications such as mitochondria 
dilation (A and D), nucleus chromatin condensation (B and E) as well as cellular 
vacuole formation (C and F) were examined and compared. Pink arrowheads indicate 
mitochondria swelling and nucleus chromatin clumps. Scale bar=1 in C and F; Scale 
bar= 2 in A, B, D and E.  
 85 
 
5. Pr-MPO-triggered necrotic cell death is calcium mediated 
5.1 Calcium channel blocker and calcium chelators successfully suppressed Pr-
MPO induced cell death in various cancer cell lines 
Our integrated results had suggested a necrotic-like cell death occurring in Pr-MPO-
incubated cells, there was no further evidence yet for the molecular mechanism 
underlying its anticancer activity. Necrosis has been considered as a passive and 
random form of cell death. In the past decades, while apoptotic cell death has been 
well characterized both at genetic and biochemical levels, the notion of necrosis has 
become progressively vague (Zong and Thompson 2006). Despite the idea that 
necrosis is an uncontrolled and default form of cell death, accumulating studies and 
evidence have suggested that this may not be true. Necrotic cell death can be a 
regulated event that contributes to development and maintenance of organismal 
homeostasis. There are more possibilities behind a necrotic face, emerging new terms 
such as autosis (Liu and Levine 2014), necroptosis (Degterev, Huang et al. 2005), 
pyroptosis (Cookson and Brennan 2001), oncosis (Majno and Joris 1995) and 
lysosomal cell death (Guicciardi, Leist et al. 2004) have been used to describe non-
apoptotic cell death that displays a controlled mode of cellular suicide. 
Necrotic cell death is not the result of one well-described signaling cascade but is the 
consequence of extensive crosstalk between several biochemical and molecular events 
at different cellular levels. Therefore, important mediators and downstream signaling 
pathways that are involved in necrotic cell death initiation, propagation and execution 
have been well characterized and documented. Recent findings on TNF-induced 
necrotic cell death in L929 cells in addition of pan-caspase inhibitor zVAD-fmk have 
uncovered a pivotal serine/threonine kinase RIP1 (receptor-interacting protein kinase) 
which contains a death domain and acts as a central initiator of necroptosis 
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(Vercammen, Beyaert et al. 1998). Calcium and reactive oxygen species (ROS), the 
well-known main players in apoptosis, whose contribution to necrotic cell death 
propagation and execution have also been reported, directly or indirectly provoke 
damage to proteins, DNA and lipids which culminates in cellular function collapse.  
Cell death mediators and essential protein factors engaged in Pr-MPO-induced 
necrotic cell death process were comprehensively investigated in our study. 
Necrostain-1, an allosteric inhibitor of RIP1 kinase, has been widely used to examine 
the contribution of RIP1K in necroptotic cell death (Degterev, Hitomi et al. 2008). 
Application of necrostatin-1 or genetic silencing of RIP1 kinase failed to block Pr-
MPO induced cell death, which excluded out the probability of RIP1K dependent 
necroptosis (Figure 13 A and B). RIP silencing efficiency by siRNAs was validated 
by western blot analysis. Previous study from our laboratory had also assessed the 
role of ROS in Pr-MPO-mediated cell death. Total intracellular ROS level as well as 
mitochondrial ROS production were examined with fluorescent probes DCFDA and 
Mitosox, respectively. To our surprise, Pr-MPO at the concentration capable of 
substantial cell killing (5µM) didn’t engender any detectable cellular ROS. ROS 
inhibitors targeting at different ROS origins and repertoires could not impair the 
ability of Pr-MPO in cytotoxicity, implying an irrelevant concern of ROS in Pr-MPO 







Figure 13. Inhibition of RIP1 kinase fails in reverting Pr-MPO-mediated cell 
death. (A) Necrostatin-1, a pharmacological inhibitor of RIP1, was administrated to 
cells at indicated concentrations for 2h, followed by 18h treatment of 5µM Pr-MPO. 
Cell viability was subsequently conducted with crystal violet assay (B) Genetic 
intervention of RIP1 was achieved by transfection of Hela cells with 50nM siRNAs 
for 48h. Post-transfected cells were subsequently incubated with Pr-MPO (2.5, 5µM) 
for additional 18h. Pr-MPO cytotoxicity at the given doses was analysed by crystal 
violet assay. One subset of cells were harvested and cell lysate was subjected to 
western blot to validate siRNA silencing quality; while the other subset of transfected 








Next, the involvement of calcium in regulation of necrotic cell death by Pr-MPO was 
also investigated by using an inorganic calcium channel blocker CoCl2, which non-
specifically blocks calcium influx across plasma membrane. Cells were cultured in 
complete DMEM medium containing 100µM of CoCl2 for 2h prior to 18h Pr-MPO 
exposure at indicated doses (Figure 14 A). Both dead cells and viable cells were 
collected, stained with PI and subjected to flow cytometry analysis to evaluate cell 
death percentage. The extent of cell death was compared between samples treated 
with Pr-MPO in the presence or absence of calcium channel blocker CoCl2 at the 
concentration of 100µM. Single-parameter histograms produced a single distinct peak 
(grey shade) representing the population of viable cell; a tiny flat peak standing for 
dead cell population (red shade) was shifted toward the right in the histogram. 
Incremental doses of Pr-MPO increased cell death from 23.38% to 43.11%, as 
evidenced by the augmented peak area in red shade. Interestingly, cell death inhibition 
was unexpectedly achieved with the calcium channel blocker CoCl2 with a 
pronounced reduction in dead cell population. Most strikingly, pre-incubation with 
CoCl2 resulted in a virtually complete inhibition of cell death by Pr-MPO; 
comparable cell death % to cells treated with vehicle control. Also, overnight 
incubation with 100µM CoCl2 as a single agent had a negligible effect on cell 
viability. As this stark suppression of cell death attained by CoCl2 was far beyond 
expectation, it provided the impetus for a more detailed analysis of the impact of 
calcium signaling on Pr-MPO-induced cell death.  
To confirm the involvment of Ca2+, I also employed two commonly used calcium 
chelators, Bapta-AM, a cell permeant calcium chealtor, which is highly selective for 
Ca2+ ion and can be used to clear and scavenge intracellular calcium level, and EGTA, 
a cell non-penetrable calcium chelating reagent, hence mopping up the extracellular 
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pool of Ca2+. Compared to the better known EDTA, EGTA has a lower affinity 
for Mg2+, making it more selective for calcium ions. Cells pre-incubated with 5µM 
Bapta-AM or 1mM EGTA for 2h followed by 18h of incubation with indicated doses 
of Pr-MPO were subjected to flow cytometry analysis. As indicated in Figure 14, B 
Pr-MPO induced cell death (PI positive staining 50%) was drastically reduced to 10% 
and 20% by EGTA and Bapta-AM, respectively. Cells incubated with high 
concentrations of calcium chelators did not show any untoward effect on cell viability. 
Dead cell percentage was quantified and statistical significance was presented from 























Figure 14. Calcium channel blocker and calcium ion chelators successfully 
restore Pr-MPO-mediated cell viability loss. (A). Cells pre-treated with or without 
100µM calcium channel blocker CoCl2 were subsequently incubated with 5µM Pr-
MPO for 18h. (B). In another set of experiment, calcium chelating reagents, EGTA 
(1mM) and Bapta-AM (5µM) were exploited before Pr-MPO administration for the 
same incubation period. After treatment, cells attached on the plate and floating in the 
supernatant were all collected and stained with PI for cell death assessment by flow 
cytometry. (C). Statistical significance of flow cytometry results was obtained with 
three sets of independent experiments. Data are shown as means ± s.e.m of three 
independent experiments; *, p < 0.05; **, p<0.01, as compared with untreated control. 
 
Post-treatment cell morphology is shown in Figure 15. Again, calcium modulators 
effectively prevented cells undergoing necrotic morphological alteration by Pr-MPO. 
Cells that had received single treatment of calcium modulators exhibited a slight 
modification in cell morphology and a reduction in proliferation rate, which were 




Figure 15. Calcium modulators post-treatment cell morphology. (A). Cells were 
pre-treated with 100µM CoCl2 ,(B) 1mM EGTA or 5µM Bapta-AM prior to 18h 
incubation of 5µM Pr-MPO. After drug incubation, cell morphology in the presence 
and absence of calcium modulators was recorded by using transmitted light 
microscopy.  
 
Cell death exerted by short-term incubation with Pr-MPO has been sturdily proved to 
be blocked by calcium modulators. Whether this inhibitory effectiveness of cell death 
could be extended to impact long term cell proliferation and survival, long-term 
survival ability of rescued cells was verified with colony forming assay.  Following 
the same incubation conditions as in the above mentioned experiments, cells were 
subsequently trypsinized, counted and re-plated onto 100mm petri dish. After 14 days 
of incubation, formed colonies were visualized by staining the petri dish with crystal 
violet. Apparently, cell clonogenic ability was significantly reduced with increasing 
doses of Pr-MPO. Cells completely paralyzed in their ability to form colonies when 
administrated with 5µM Pr-MPO. However, the presence of 100µM CoCl2 aforehand, 
remarkably restored the colony forming activity despite the presence of Pr-MPO. 
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(Figure 16 A). Similarly, calcium chelator EGTA also exhibited virtually complete 
protection of cell proliferation in cells insulted with Pr-MPO; whereas Bapta-AM 
could only rescue partially the cells’ clonogenic ability (Figure 16 B). In good 
agreement with flow cytometry analysis results, both EGTA and Bapta-AM rescued 
cells from Pr-MPO induced cell death to a great extent, in which a sheer rescue in cell 
death was endeavoured by either CoCl2 or EGTA; only a fractional cell death, 
however, was prevented by Bapta-AM. As all these tested calcium modulators target 
different calcium pools, such as CoCl2 blocks extracellular calcium entry through 
calcium channels residing in the plasma membrane, EGTA scavenges the extracellular 
calcium to prevent calcium influx and Bapta-AM after penetrating into the cells is 
trapped in the cytosol and chelates intracellular calcium, our results strongly implicate 
calcium in the anti-tumor activity of Pr-MPO. 
 
Figure 16. Pr-MPO-induced cologenicity reduction is reversed by calcium 
modulators. Cells were pre-treated with either calcium channel blocker CoCl2 at 
100µM (A) or calcium ion chelators EGTA 1mM or Bapata-Am 5µM (B) for 2h, 
followed by Pr-MPO treatment for 18h. Treated cells were collected, counted and 
replated onto 100mm petri dish for colony formation. Colonies were then visualized 





Interestingly, we noticed that EGTA and CoCl2 were more potent than Bapta-AM in 
rescuing the cells from Pr-MPO-induced cell death. Regular EGTA, unlike Bapta-AM, 
is a membrane impermeant calcium modulator, and usually does not chelate the 
intracellular pool of calcium unless the cell membrane has been pre-permeabilized. 
Nevertheless, to the extent that extracellular calcium influences intracellular events, 
many of which are dependent on cellular calcium uptake, EGTA-mediated chelation 
of extracellular calcium will have an indirect effect on the intracellular levels as well. 
This piece of data provides us the first glance that Pr-MPO induced cell death is 
probably calcium-mediated, however, the detailed mechanism of how Pr-MPO 
triggered aberrant calcium signals, especially cellular calcium mobilization, required 
further investigation and was the major focus of my following work.  
5.2 Calcium modulators effectively blocked Pr-MPO-induced autophagy  
Having observed the ability of calcium chelators to rescue cells from Pr-MPO, I next 
tested whether autophagy induced by Pr-MPO was also regulated by calcium.   To do 
so, cellular calcium was chelated with EGTA or Bapta-AM, and its effect on the 
autophagic markers p62 and LC3-II were determined by Western blot. Notably, a 
clear inhibition of Pr-MPO-induced LC3-II upregulation was obtained in the presence 
of EGTA and CoCl2, while the same effect was not noticeable with Bapta-AM pre-
incubation (Figure 17A and B). This indicates that, rather than intracellular calcium, 
the extracellular-intracellular calcium mobilization/oscillation probably plays a more 
fundamental role in regulation of both Pr-MPO-induced cell death and autophagy 
signaling pathways. Furthermore, to our surprise, we noticed a lower band around 
46kDa appeared under the full length of p62 triggered by Pr-MPO. Recent studies 
have intensively reported that p62 is the target for caspase-6 and 8 cleavage, resulting 
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in two cleavage fragments of 46kDa and 30kDa.  Complete cleavage of p62 was also 
seen in a concentration-dependent manner with protease calpain1 (Joanna M et al, 
2010). In line with these findings, our result showed that the cleaved product of p62 
(46K) was completely inhibited upon calcium chelation (Figure 17A), thus indicating 
a role for a calcium dependent protease (such as calpain) in the biological activity of 
Pr-MPO.  This observation brings us back to our observed decrease in p62 expression.  
Based on the data obtained so far, it is highly conceivable that the decrease of p62 
expression may not really reflect autophagosome flux, but be a consequence of 
calpain protease-mediated cleavage. Given the discrepancy between p62 degradation 
and other autophagic markers, along with the apparent production of a cleavage 
product in Pr-MPO-treated cells, the cleavage of p62 appears likely regulated 




Figure 17. Autophagy event induced by Pr-MPO is effectively blocked by using 
calcium modulators. (A) Hela cells were pre-treated with 1mM EGTA, 5µM Bapta-
AM or (B).100µM CoCl2 respectively, followed by 2.5 and 5µM Pr-MPO incubation 
for 18h and cell lysate was subjected to immunoblotting. Total cellular protein 
expression of p62, LC3I, LC3II and loading control Actin were detected by probing 













6. Pr-MPO evoked a robust intracellular calcium response 
6.1 Pr-MPO stimulation triggered an increase in intracellular calcium level 
Altogether, our preliminary results provided strong evidence for the probable 
involvement of calcium signaling as the underlying mechanism of Pr-MPO-induced 
cell death, and therefore tempting enough to focus my future work on unrevealing the 
functional biology of this interesting molecule.  
To further understand the biological mechanism by which calcium signaling was 
engaged and transduced in response to Pr-MPO, the fluctuation in the amount of 
calcium in cytoplasm over time was visualized by using a non-ratiometric fluorescent 
probe Fluo4-AM. Cells grown on a fibronectin pre-coated glass chamber for 24h were 
loaded with dye Fluo4-AM, diluted to a final concentration of 2µM in Tyrode’s buffer. 
Fluo4-AM loaded specimens were maintained in phenol red-free DMEM medium 
supplemented with 10% FBS to eliminate the high signal-to-noise ratio and imaged 
under a confocal microscope equipped with a 37oC chamber and supplied with 5% 
CO2. Live-cell images were gathered with a confocal microscope at 5-sec intervals 
over a total period of 5 minutes. Pr-MPO was given at the indicated time point after 
1min acquisition of baseline. With an autofocus system, the confocal microscope 
managed to produce a sharp and well-focused imaging video for the entire 
investigation in spite of intermittent drug administration. As illustrated in Figure 18 A, 
application of Pr-MPO immediately elicited a rapid increase in intracellular calcium 
level (at 90s) that displayed a 1.3-fold increase in Fluo4-AM fluorescence intensity 
(Figure 18B). Pr-MPO-evoked intracellular calcium elevation gained steadily over 
time and eventually entered into a plateau phase (Fluo-4: F/F0= 2.31±0.022) at the 
end of the experiment. This intracellular calcium fluctuating pattern by Pr-MPO was 
compared with thapsigargin, the most widely used inhibitor of sarco-endoplasmic 
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reticulum Ca2+-ATPase (SERCA) in mammalian cells, which served as an objective 
reference in this case. Unlike Pr-MPO, 1µM thapsigargin stirred up a biphasic peak 
increase in intracellular calcium, which consisted of an initial transient peak increase 
of 1.86 fold and followed by a long-lasting decline of calcium concentration noticed 
at 420s (Figure 18C). The initial transient rising phase (Fluo-4: F/F0=2.86±0.26) and 
the slow declining phase of intracellular calcium (Fluo-4: F/F0=2.75±0.272) in 
response to thapsigargin reflected a blockade of Ca2+ uptake into the ER and 
subsequently resulted in the influx of extracellular calcium via store-operated calcium 
entry (SOCE) channels. Distinctive pattern of [Ca2+]i elevation by Pr-MPO was 














Figure 18. Pr-MPO evokes a robust intracellular calcium response. (A). Hela 
cells grown on the 4-well glass-bottom chamber were loaded with 2µM intracellular 
calcium indicator Fluo4-AM. Pr-MPO-induced calcium response was examined by 
time-lapse confocal imaging at a pre-determined 5-sec interval over a total acquisition 
duration of 5min. A series of calcium images were captured at indicated timepoints. 
Scale bar, 20µM. (B) Relative fluorescence intensity (∆F) values were determined 
over the initial fluorescent intensity of Fluo4-AM. Changes in Fluo4-AM 
fluorescence evoked by Pr-MPO 5µM were shown as means ± s.e.m. from 20 regions 
of interest (ROI) from a single coverslip, representative of at least three independent 
experiments. (C). Images similar to those shown in (A), but with cells treated with 
2µM thapsigargin; each representative of at least three independent experiments. 
Scale bar, 20µM (D). Changes in Fluo4-AM fluorescence evoked by thapsigargin 
2µM were shown as means ± s.e.m. from 20 regions of interest (ROI) from a single 









6.2 Pr-MPO-evoked intracellular calcium elevation was in a dose dependent 
fashion 
Next, the dose dependency of the effect of Pr-MPO on intracellular free calcium 
elevation was further characterized with different concentrations of Pr-MPO (2.5, 5 
and 10µM). As shown in Figure 19, fluo4-AM fluorescence readout was grouped into 
three categories based on the concentrations of the stimuli: low, medium, and high. At 
a low concentration of Pr-MPO, Fluo4-AM labelled cells emitted a very weak signal 
with a limited increase in fluorescence intensity normalized to the basal line (Fluo-4: 
F/F0=1.3), indicating a small amount of free calcium increase in the cytoplasm. The 
amplitude of intracellular calcium increase at medium and high doses of Pr-MPO was 
much higher. Most of the cells under these two conditions showed a rapid rise in 
intracellular calcium in a dose-responsive manner, as evidenced by a 0.7-fold (Fluo-4: 
F/F0=1.7) and 1-fold (Fluo-4: F/F0=2) peak increase in fluorescence intensity, 
respectively. This incremental value of intracellular calcium eventually reached a 
plateau phase of elevated level. 
 
Figure19. Magnitude of intracellular calcium elevation is Pr-MPO dose 
dependent.  Fluo4-AM loaded cells were given various concentrations of Pr-MPO 
ranging from (2.5 to 10µM). Changes of Fluo4-AM fluorescence intensity in response 
to Pr-MPO was plotted.  
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6.3 Calcium signal was enhanced in lysosomes by Pr-MPO  
Of note, during the process of montage analysis, a very intriguing phenomenon was 
observation, i.e., besides the diffused cytoplasmic fluorescent signal exerted by Pr-
MPO, a form of perinuclear fluorescent aggregates unexpectedly appeared during the 
process of calcium imaging acquisition (see white arrowheads in Figure 18 A). In an 
attempt to take a closer look at the nature of these fluorescent aggregates, a higher 
magnification objective (60x) was employed to yield a finer resolution of image detail. 
Under high-resolution microscope, a number of fluorescent puncta representing 
“calcium bodies” surprisingly emerged in close proximity to the nucleus a short while 
after Pr-MPO treatment (see red arrowhead in Figure 20). Despite a uniform increase 
of cytosolic calcium, representative images from Figure 20 manifested that Fluo4-AM 
fluorescence in these aggregate-like calcium puncta was persistently elevated in a 
temporal manner, which was in proportion to the amount of [Ca2+] in those small 
particles/vesicles. A zoomed-in image of fluorescent punctate from the red box is 
presented at the bottom right in Figure 20. The red arrowheads indicate the occurrence 
















Figure 20. High magnification images reveals fluorescent calcium punctate 
formation by Pr-MPO. Time lapse imaging showing Fluo4-AM response of same 
field of view of Hela cells before and after application of Pr-MPO. Calcium imaging 
was recorded over 5mins (5sec interval). Images of different time intervals displayed 
the fluctuation in the amount of calcium in cytoplasm. Flou4-AM fluorescence is 
proportional to intracellular calcium concentration. Red arrowhead indicates the 
aggregate-like calcium punctate adjacent to the nucleus. Zoomed image of calcium 
punctate from the red box is shown at the bottom right. Scale bar, 20µm. 
 
 
The evidence of “calcium body” formation in response to Pr-MPO stimulated me to 
classify the cellular identity of these punctate vesicles which served as calcium 
compartments. Dynamic changes of calcium derived from extracellular milieu and/or 
intracellular calcium stores is precisely tuned and orchestrated by a toolkit of calcium 
channels, pumps and exchangers (Clapham 2007). By far, the major and best-studied 
calcium repertoire in eukaryotic cells is endoplasmic reticulum, possessing a well-
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defined system for the regulation of intracellular calcium mobilization. Mitochondria 
as sensors and regulators of calcium signaling can also transiently sequester certain 
amount of calcium circumstantially. Furthermore, a high concentration calcium pool 
has also been discovered in a variety of acidic compartments in both prokaryotic and 
eukaryotic cells (Pozzan, Rizzuto et al. 1994). In this regard, lysosome, one of the 
major acidic organelles, has gained back the appreciation in recent studies as a vital 
calcium store in animal cells. Dysfunction of acidic calcium stores and deregulation of 
calcium signaling have been reported to result in certain human diseases (Styrt, 
Pollack et al. 1988, Shen, Wang et al. 2012).  
To validate the identity of cellular compartment where the vesicles reside, I undertook 
to decipher the sub-cellular localization of these calcium puncta. Morphologically, 
dotted calcium puncta engendered by Pr-MPO had no resemblance to the ER or the 
mitochondria, however, the appearance was indicative of probable acidic vesicles 
comprised of endolysosomal system.  Therefore, to study the acidic vesicles, cell were 
firstly labelled with 50nM LysoTracker® Red DND-99, a red-fluorescent dye for 
labelling and tracking acidic organelles in living cells, and incubated for 30mins at 
37°C. Cells probed with LysoTracker were thoroughly washed with Tyrode’s buffer 
and loaded with 2µM Fluo4-AM calcium indicator for 30mins at 16°C. This 
sequential loading process was of particular importance to avoid competitive uptake 
of fluorescent probes into lysosomes which may result in uneven fluorescent signals. 
The positions of green (Fluo4-AM) and red (Lysotracker) particles were determined 
separately by using dual-excitation wavelength time lapse imaging. The image 
sequence in Figure 21 illustrates the presence of calcium puncta residing at the same 
location of lysosome. Figure 21 (a) and (d) were scanned from a detector channel 
filtered for the emission spectrum of Fluo4-AM  (intracellular calcium) when excited 
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with an argon-ion laser at 488nm; while Figure 21 (b) was the channel filtered to 
gather fluorescence emission from LysoTracker (lysosomes) when excited with a 543-
nanometer helium-neon laser. Apparently, prior to Pr-MPO application, cells from 
Figure 21 (a) exhibited a homogeneous distribution of Fluo4-AM staining in the 
cytosol, without significant evidence of calcium puncta formation. Small, round, 
LysoTracker-stained vehicles neighbouring the cell nucleus represented lysosome 
organelles in Figure 21 (b). Since there was no formation of calcium punctate, the 
merged colour image didn’t provide any proof of specific co-localization (Figure 21 
c). Once cells were treated with Pr-MPO, an incremental fluorescence intensity was 
observed in both the cytoplasm and the small vesicles (Figure 21d), exemplified by 
those bright and dotted particles dispersed within the cells. Image slices acquired in 
red channel showed a sustained signal of LysoTracker with no increase in the total 
fluorescence intensity nor the total mass of lysosomes throughout the whole session 
(Figure 21e). Digital images of combined fluorescence from two channels revealed a 
perfect co-localization of calcium puncta and lysosomes. The red fluorescence emitted 
from LysoTracker was gradually overridden by the increasing green signal of Fluo4-
AM and displayed an overlapped yellow colour in Figure 21 (f). Clearly, these data 
provide strong evidence that the small aggregate-like puncta serving as intracellular 
calcium stores are lysosome vesicles.  Taken together, our experimental evidence 
suggested that the increase in [Ca2+]i by Pr-MPO consisted of [Ca2+] elevation in both 






Figure 21. Confocal microscope shows the co-localization of Pr-MPO-induced 
calcium puncta and lysosomes in correlation with time. For each stack (t, time), 
images were obtained in two channels in 5-sec interval over a total time period of 
5mins. Hela cells were dual stained with calcium and lysosome indicators; Green 
signal (a and d), Fluo4-AM; red signal (b and e), LysoTracker® Red DND-99. Upon 
5µM Pr-MPO treatment, calcium puncta in green fluorescence appeared in proximity 
of the nucleus, where they were localized with lysosomes labelled in red. Digital 
images in combination of two colour channel were shown in (c) and (f). Yellow signal 
in image (f) represented the combined two signals from one cellular location. Images 











7. Intracellular calcium influx acted as an upstream mediator of Pr-MPO cell 
demise 
So far, our experimental results had demonstrated a strong association of intracellular 
calcium signaling with Pr-MPO anti-tumor activity. More interesting are findings of 
Pr-MPO-induced intracellular calcium elevation, especially in acidic compartments, 
more specifically the lysosomes. In light of these findings, the next question was 
whether the increase in intracellular calcium was an early event responsible for Pr-
MPO-mediated cell death. To address this, same cell imaging experiment was 
repeated in three different scenarios: (i) cells were pre-incubated with 5µM Bapta-AM 
to scavenge intracellular calcium, (ii) perfused with calcium free medium containing 
1mM EGTA to remove extracellular calcium completely, or (iii) pre-treated with 
100µM CoCl2 to block extracellular calcium entry. Cells were pre-treated for 2 h with 
these scavengers/inhibitors prior to the addition of 5µM Pr-MPO and subjected to 
real-time intracellular calcium imaging. Time-lapse imaging video clips were 
recorded and high magnification images representative of different time intervals are 
presented in Figure 22. It is readily discernible from Figure 22 A(a), a reproducible 
1.2-fold enhancement in Fluo4-AM fluorescence intensity was detected in Pr-MPO-
treated cells together with an appearance of the green fluorescent puncta, indicating 
elevated [Ca2+] in both cytosolic and lysosomal compartments. The event of [Ca2+]i 
elevation occurred rapidly after Pr-MPO stimulation, which sustainably increased 
over time and eventually entered into a steady phase at the end of the acquisition. 
Interestingly, lowering the intracellular calcium by the administration of 5µM Bapta-
AM protected cells from Pr-MPO-induced calcium accumulation in the different 
cellular compartments. The cytoplasmic Fluo4-AM fluorescence signals remained 
unaltered without detectable fluorescence puncta formation (Figure 22A (b)). The 
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elevated [Ca2+]i fraction reflected by the proportional increase in Fluo4-AM 
fluorescence differed significantly between cells treated with Pr-MPO alone and those 
treated with Pr-MPO plus 100µM CoCl2. Results shown in Figure 22 A(c) suggested 
that CoCl2 blocked extracellular calcium entry into the cells and attenuated Pr-MPO-
induced cytosolic and lysosomal calcium increase. In order to further examine the 
effect of extracellular calcium on Pr-MPO-mediated [Ca2+]i increase, the treatment 
was performed in calcium-free conditions in the presence of 1mM EGTA. Likewise, 
results from Figure 22A (d) also showed that chelated calcium-free medium 
completely abolished Pr-MPO-exerted effects on [Ca2+]i.  The data shown in Figure 
22B represent the mean and error bars from three independent experiments. 
The addition of various calcium modulators had successfully attenuated both events 
of Pr-MPO-induced cytotoxicity and augmentation of intracellular calcium 
concentration, which provided strong testimony that the degree of Pr-MPO-induced 
cell death closely correlated with the observed intracellular calcium changes. It is 
noteworthy that by lowering intracellular calcium with Bapta-AM, a similar inhibitory 
effect was observed in terms of the decreases in cytosolic and lysosomal calcium to 
that of the other two extracellular calcium modulators (EGTA and CoCl2). However, 
besides the success in inhibition of intracellular calcium elevation, only a partial 
rescue in Pr-MPO-induced cell death was observed with Bapta-AM. This might be 
due to the inefficiency of Bapta-AM in chelating calcium fluxed from extracellular 
environment, the remnant of which was sufficient enough to augment the downstream 
cell death signaling.  
These findings had conceivably established that Pr-MPO-mediated anti-tumor activity 
was calcium ion-dependent. In particular, Pr-MPO-induced aberrant calcium influx 
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Figure 22. Calcium modulators successfully attenuate Pr-MPO-elevated [Ca2+] in 
both cytoplasm and lysosomes. (A) Previous observation in Pr-MPO-induced 
cytosolic calcium elevation and lysosomal calcium puncta formation (a) was 
examined in three calcium scenarios: (b) Fluo4-AM loaded cells were pre-incubated 
with 5µM intracellular calcium scavenger Bapta-AM; (c) perfused with calcium-free 
DEME medium in the presence of 1mM EGTA; (d) pre-treated with 100µM CoCl2. 
Treatments from these three scenarios were conducted 2h before calcium imaging 
analysis. Time lapse images were captured at a pre-determined 5-sec interval over a 
total acquisition course of 5mins. Representative images illustrating the changes in 
intracellular calcium were selected. (B) Data represent means ± SEM from at least 
three independent experiments in which 20 cells were quantified per experimental 
point. Relative fluorescence intensity ∆F/F was obtained by drawing a ROI around the 
entire cell. Scale bar, 20µM. 
 
The most important characteristic of AM ester indicators with various Fluo 
derivatives is the ability to enter the cells by penetrating through the plasma 
membrane. Esterase activity which is required to hydrolyse AM ester residue of the 
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dye is not exclusively present in cytosol, but also available in other subcellular 
compartments. Therefore, incubation with AM ester dyes may not only result in 
loading of the indicators into the cytosol, but also into various organelles. Researchers 
working with Fluo4-AM calcium indicator mostly have incurred a subcellular 
compartmentalization in lysosomes and other acidic vacuoles, which complicated the 
interpretation of Fluo4-AM signals. Be that as it may, owing to this drawback of 
Fluo4-AM, we were able to capture the first evidence on lysosomal calcium influx by 
Pr-MPO. Therefore, to validate these results, it was imperative to employ a more 
lysosomal-targeted approach for an accurate measurement of free Ca2+ inside 
lysosomes. Ratiometric measurements by co-loading of a single wavelength Ca2+ 
sensitive dye and Ca2+ insensitive dye have been commonly applied for monitoring 
relative changes in lysosomal calcium concentration. The ratio value of two 
fluorescence intensity allows correction for artefacts resulting from photo damage, 
dye overloading, and pH quenching and other effects.  
Therefore, to gain further insight into the effect on lysosomal calcium, I made use of 
the cell-impermeant dextran-conjugated fluorescent probes, Calcium Green-1 dextran 
(10,000 MW, Ca2+ sensitive ) and Texas Red dextran (7,000 MW, Ca2+ insensitive). 
Cells were co-incubated with these probes for 16h to allow for internalization into the 
lysosomes by endocytosis. Dual dye loaded cells were washed and kept in fresh 
DMEM medium for additional 4h before conducting calcium imaging analysis by 
Time-laspe confocol microscopy. Small, granular lysosomes, diffusively scattered 
throughout the cytoplasma, were highly dynamic and mobile, embodied by active and 
salutatory moving fluorescent puncta in resting cells (see movie clip). Emission 
fluorescence intensity from calcium green-1 was reinforced over the time course of 
Pr-MPO treatment (highlighted with white arrowheads), indicating that calcium influx 
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or elevation took place inside the lysosomes (Figure 23 A left pannel). Fluorescence 
signals collected from calcium non-responsive dye Texas Red remained constant from 
start to finish (Figure 23 A, middle pannel). Data from three independent experiments 
showed a statistically significant increase of 1.67-fold in the peak Fluo4-AM 
fluorescence signal normalized to that of Texas Red (Figure 23 B). The amplitude of 
ratiometric fluorescence increase was slightly lower than that obtained with Fluo4-
AM, which could be explained by the deficient amount of cytosolic calcium. To that 
end, in pace with green fluorescent intensity increase, overlay images from the two 
channels revealed a merged colour transition from reddish into yellowish/greenish 
(Figure 23 A, right panel). White arrowheads from overlay channels point to the fact 
that punctate vesicle calcium influx took place in the subcellular compartment of 
lysosome. By utilizing this organelle-specific calcium indicator, these results strongly 
corroborated Pr-MPO-modulated lysosomal calcium influx. Furthermore, composite 
images of movie clips from three independent experiments were pooled and shown in 










Figure 23. Emission ratiometric imaging of Pr-MPO-evoked lysosomal calcium 
elevation. (A) Hela cells were cultured in DMEM medium containing 10µg/ml 
calcium binding indicator, Calcium Green-1 dextran (CG-1) and 5µg/ml calcium 
insensitive indicator, Texas Red dextran (TR) overnight. Loaded cells were washed 
and replenished with fresh medium for another 4h followed by time lapse imaging 
analysis upon Pr-MPO treatment. Left, fluorescence imaging of intraluminal 
compartment calcium (lysosome) (green channel); middle, fluorescence imaging of 
endosomes/lysosomes (red channel); right, digital images in combination of green and 
red channels. (B) The effect of Pr-MPO on the emission intensity ratio of dual single-
wavelength CG-1 and TR upon excitation of 488nm and 564nm. Data are 
representative of three independent imaging experiments. Statistical significance was 
calculated using n=30 cells for each experimental point.  
 
Ratiometric measurement of lysosomal calcium by calculation of emission 
fluorescence ratio of calcium green-1 over Texas Red corroborated our previous 
findings of lysosomal calcium influx evoked by Pr-MPO, despite the overall calcium 
elevation occurred in the cytosol. Next, to verify the association between cell death 
event and lysosomal calcium influx, the effect of calcium modulators that 
significantly blocked Pr-MPO-exerted cell cytotoxicity, was assessed on lysosomal 
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calcium influx by probing cells with lysosomal calcium indicators. Consistent with 
our earlier results, Pr-MPO treatment failed to result in noticeable lysosomal calcium 
change in pharmacologically (calcium modulators) intervened cells. In contrast to Pr-
MPO treatment alone, increment of emission fluorescence intensity was barely 
detected in CG-1 channel pre-incubated with respective calcium modulator (Figure 
24). Both intracellular and extracellular calcium scavengers had robustly inhibited Pr-
MPO-evoked lysosomal calcium response. Fluorescence signal of calcium non-
specific indicator Texas Red remained unchanged.  
Collectively, ratiometric imaging technique specific for lysosomal calcium provided 
strong support to the findings that an important mechanism of action of Pr-MPO 
involved the activation of lysosomal calcium influx. The various calcium modulators 
not only inhibited Pr-MPO induced autophagy and cell death, but more importantly, 
neutralized the effect on lysosomal calcium import. Given the critical role of 
lysosomes in autophagosome degradation during autophagy, these results argue in 
favor of a central role for lysosomal calcium influx in Pr-MPO-induced autophagy 
and cell death. Since these two biological activities of Pr-MPO took place in a 
temporal order, it is conceivable that Pr-MPO-mediated cell death is a consequence of 











Figure 24. Calcium modulators block Pr-MPO-evoked lysosomal calcium influx 
by ratiometric measurement. Hela cells were co-loaded with lysosomal specific 
calcium fluorescent probes, Calcium Green-1 and Texas Red as described in Materials 
and Methods. Treated cells were further incubated with various calcium modulators at 
indicated concentrations for 2h prior to calcium imaging analysis: (A) 5µM 
intracellular calcium scavenger Bapta-AM; (B) 100µM plasma membrane calcium 
channel blocker CoCl2; (C) 1mM EGTA-containing DMEM medium. Time lapse 
confocal imaging was carried out at 5-sec interval over a total acquisition duration of 
5min. Dual channel images are representatives of different time intervals from a 






8. Lysosomal calcium influx by Pr-MPO was dependent on a dynamic proton 
gradient. 
8.1 Dissipating lysosomal pH attenuated Pr-MPO-evoked lysosomal calcium 
influx 
Calcium uptake into the acidic calcium stores, such as the lysosomes, is majorly 
mediated by either calcium pumps or exchangers. Calcium ATPase are pumps located 
in various membrane bounded organelles and plasma membrane (PMCA), which 
transport calcium against the concentration gradient from cytosol to the organelle 
lumen or extracellular environment (Carafoli and Brini 2000). In invertebrate 
eukaryotic microorganisms such as trypanosomes, yeast, and Dictyostelium, calcium 
ATPase pumps of similar subtypes have been discovered residing in the 
acidocalcisomes, vacuoles, Gogi and lysosome-related organelles (Cunningham and 
Fink 1994, Moniakis, Coukell et al. 1999). Unfortunately, the existence of calcium 
ATPase pumps in animal cells has still not been reported. Therefore, calcium ATPase 
pumps were unlikely to be the primary candidate in explaining the mechanism of 
lysosomal calcium influx by Pr-MPO. An earlier study from Swanson’s group had 
reported that calcium mobilization in acidic vascular compartment was able to be 
achieved by utilizing the large concentration gradient of protons across the 
membranes of acidic calcium stores (Christensen, Myers et al. 2002). This process 
required calcium hydrogen exchangers (CAXs) which have been identified in many 
invertebrate and lower vertebrate organisms, however, genome coding of CAXs are 
absent in mammalian genomes. Nonetheless, the pH-dependent regulation of 
lysosomal calcium has been reported in mouse macrophages. The luminal pH increase 
mediated by bafilomycin A1 (Bal-A1) or concanamycin, specific inhibitors of 
vacuolar-type H+-ATPase, decreased lysosomal calcium concentration. One 
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possibility to explain this paradox is the calcium-hydrogen exchange activity may not 
be attained by a single protein, but a synergetic effect of sodium hydrogen exchangers 
and sodium calcium exchangers. Encouraged by this reported evidence, I set out to 
investigate whether pH was accounted for a casusative role in lysosomal calcium 
regulation in Pr-MPO treated cells.  
First, fluorescence intensity emitted from Fluo4-AM was compared in cells with Pr-
MPO single treatment and PrMPO plus Bal-A1 by time lapse confocal imaging. After 
running the baseline, cells were given 1µM Baf-A1 to block the proton concentration 
gradient for 1min before the addition of 5µM Pr-MPO. To our great surprise, results 
illustrated in Figure 25B demonstrate that treatment with Bal-A1 pronouncedly 
abolished Pr-MPO-exerted lysosomal calcium entry, which was evidenced by the 
absence of acidic vesicular puncta. Blockade of proton translocation from cytosol to 
lysosomal lumen resulted in an increase in pH (alkalinization) and subsequent 
dissipation of the calcium current entering into lysosomes. However, cytosolic 
fluorescence signals enhanced by Pr-MPO was not affected by Bal-A1. A 0.6-fold 
increase (∆F/F0 = 1.64 ± 0.77, n = 60 cells, Figure 25 C) in Fluo4-AM fluorescence 
intensity, which was proportional to the amount of cytosolic calcium, was detected in 
the process of imaging. Lacking lysosomal calcium signals in Bal-A1-pretreated 
scenarios could be one of the possibilities contributing to a lower amplitude in total 
Fluo4-AM intensity compared with the situation of Pr-MPO single treatment (∆F/F0 
= 2.31 ± 0.022, see Figure 16B). Relative fluorescence intensity of Fluo4-AM pooled 
from three independent experiments is shown in Figure 25C. Statistical significance 






Figure 25. Inhibition of H+ accumulation by acidic organelles attenuates the 
increase in lysosomal [Ca2+] evoked by Pr-MPO. Cells loaded with Fluor4-AM 
calcium indicator were subjected to time-lapse confocal imaging. Intracellular 
calcium level in response to Pr-MPO treatment was measured with and without proton 
pump inhibitor Bal-A1 (A) Fluo4-AM loaded specimen was treated with 5µM Pr-
MPO alone; (B) Cells were pre-incubated with 1µM Bal-A1 for 2min, followed by 
5µM Pr-MPO stimulation for pre-designed duration. A series of images (C) 
Fluorescence curve as a result of CG-1/TR emission fluorescence ratio reflected the 
variability in lysosomal calcium concentration. Statistical significance was derived 
from three independent experiment. Fluorescent intensity was measured by drawing a 
ROI over a lysosome-gathered region.  
 120 
 
To corroborate the Fluo4-AM imaging results, the inhibitory effect of Bal-A1 on 
lysosomal calcium was measured again with ratiometric imaging (Figure 26). 
Fluorescent probe loading method and real-time calcium imaging procedure were 
complied with previous experimental conditions. Upon visualizaiton in the 
microscope, both dyes were internalized into tubular and vesicular structures, typical 
of lysosomes and related organelles. Pr-MPO-evoked calcium influx into lysosomal 
lumen was denoted by a stronger fluorescent signal of CG-1 and an increasing yellow 
colour in green-red merged channel (Figure 26A). Conversely, inhibition of H+-V-
ATPase with Bal-A1 was able to blunt Pr-MPO-evoked lysosomal calcium response. 
Illustrated in Figure 26B are a series of images captured for the combination treatment 
with Bal-A1 and Pr-MPO; no detectable changes in fluorescent intensity was 
observed in the individual channel throughout the whole imaging session. Composite 
images of time-lapse video from three independent experiments were analysed. 
Ratioametric fluorescence intensity of CG-1 over TR were calculated in these two 
tested scenarios (Bal + Pr-MPO ∆F/FCG-1/TR=1.07 ± 0.97 / Pr-MPO ∆F/FCG-1/TR=1.63 














Figure 26. Ratiometric measurement assures the dependency of lysosomal 
calcium uptake on proton electrochemical gradient in Pr-MPO treated cells. 
Cells internalized with ratiometric calcium probes CG-1 and TR underwent time-lapse 
imaging analysis monitoring lysosomal calcium changes upon Pr-MPO treatment (A) 
After 1min baseline stabilization, a series of images indicative of lysosomal calcium 
level were captured upon single treatment of Pr-MPO; (B) In another set of 
experiment, cells were pre-incubated with 1µM Bal-A1 for 2min, followed by 5µM 
Pr-MPO stimulation for another 2 min. Images from each channel (green and red) at 
indicated time intervals were captured and merged (yellow). (C) Fluorescence curve 
as a result of CG-1/TR emission fluorescence ratio reflected the variation trend in 
lysosomal calcium concentration. Statistical significance was derived from three 
independent experiment. Fluorescent intensity was measured by drawing a ROI over a 
lysosome-gathered region.  
 
In summary, high concentration of Bal-A1 dissipated H+ gradient promptly by 
paralyzing V-ATPase activity, which lead to a consequential disruption of calcium 
flow transported from cytosol into lysosomal lumen. This result is in agreement with 
the notion that lysosomal calcium uptake is dependent upon a proton 
electrochemicalgradient that can be readily utilized to transport calcium ion uphill into 
vesicle lumen of lysosomes. Whether Pr-MPO-mediated lysosomal calcium influx 
was dependent upon an enhanced proton current across membranes of lysosome 
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vacuoles, measurements of intracellular and lysosomal pH were carried out to address 
this question. 
 
8.2 Pr-MPO increased lysosomal pH and decreased cytosolic pH 
We assessed the effect of Pr-MPO on lysosomal pH using a pair of endocytosed 
dextran-conjugated indicators: an inert marker Texas Red, dextran, 7,000MW and 
Oregon Green, dextran, 10,000MW. Both hydrophilic fluorescent probes were 
delivered into cells at a final concentrations of 10µg/mL OG and 5µg/mL TR. 
Internalized fluorescent probes selectively deposited in cell lysosomes as illustrated in 
Figure 27 A. In population of Hela cells, Pr-MPO evoked a sustained increase in OG 
fluorescence, without affecting TR signals (Figure 27A and B). Our preliminary 
results implied that Pr-MPO elicited a small increase in lysosomal pH. Bafilomycin 
A1 dissipated lysosomal acidification and was used as a positive control. In parallel, 
experiments were performed to determine intracellular pH using the cell permeant 
fluorescent indicator, BECEF-AM. Cells cultured in a 48-well plate were labelled 
with 2µM BECEF-AM, washed with HBSS, and fluorescence was measured with a 
fluorescent plate reader. Quantitative intracellular pH values in relation to the 
fluorescence readout was calibrated using a standard pH curve. Intracellular pH has 
been shown to be more alkaline in cancer cells and to be an important trigger for 
cancer cell proliferation (Pirkebner, Fuetsch et al. 2004). Resting Hela cells grown in 
a bicarbonated medium exhibited an intracellular pH of 7.78, higher than non-
neoplastic cells. Pr-MPO perturbed intracellular proton concentration and brought 
down pHi from 7.78 to 7.58 after 2min incubation, drop of which was scaled up to 
7.47 with longer incubation duration (Figure 27 D). 1µM concanamycin was applied 
as a positive control to dissipate the luminal proton of lysosomes, thus a slight 
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decrease in cytosol pH was expected. This result demonstrated that under the 
conditions where lysosomal pH was moderately increased by Pr-MPO, a 
correspondent drop in intracellular pH was expected. With an elevated [H+] in cytosol, 
the likelihood of reduction in lysosomal [H+] was very low. Therefore, Pr-MPO-
evoked  pHly increase may not be a secondary effect in response to pHi changes, but 
could be explained as a result of [Ca2+]ly uptake via Na+/H+ and Na+/Ca2+ exchangers 

























Figure 27.  Pr-MPO increases luminal pH of lysosome and decreases cytosolic pH. 
(A). Wide-field fluorescent image of cells loaded with dextran-conjugates of Oregon 
Green (OG) and Texas Red (TR) in response to 5µM Pr-MPO. (B) Summary results) 
show peaks in OG and TR fluorescence measured within 7 min of addition of Pr-
MPO. (C) Wide-field fluorescent image of cells loaded with dextran-conjugates of 
Oregon Green (OG) and Texas Red (TR) in response to 1µM Bal-A1. (D) Cells were 
loaded with 2µM BECEF-AM intracellular calcium indicator. pHi measured in 
populations of BECEF-AM labelled cells before and after stimulation with Pr-MPO 
( 2, 5 and 10 min) in the absence and presence of Pr-MPO 
 
 
Based on our imaging results and observations, we may conclude that Pr-MPO 
possessed a potent capability of evoking a globe increase in intracellular calcium as a 
function of elevation in cytosolic and lysosomal calcium. Pr-MPO-mediated cytosolic 
and lysosomal calcium uptake were attenuated by calcium modulators, which also 
inhibited Pr-MPO cytotoxicity and autophagy. This implied that Pr-MPO-evoked 
intracellular calcium response, especially lysosomal calcium influx, probably acted as 
an upstream signal that triggered subsequent events leading to cell death. 
Pharmacological intervention of electrochemical proton gradient by bafilomycin A1 
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prohibited calcium entry into lysosomes, suggesting that lysosomal calcium uptake 
was dependent on a dynamic pH gradient. Ratiometric confocal using pH fluorescent 
indicators detected a moderate increase in lysosomal pH, which further confirmed the 
dependence of [Ca2+]ly on [H+] ly. As a result of this, complementary measurement of 
cytosolic pH under the same circumstance detected a decrease in pHi upon Pr-MPO 
treatment. Whether lysosomal calcium and pH responses were direct determinants of 
Pr-MPO-modulated cell death still remains to be addressed.  
 
8.3 Involvement of lysosomal calcium in Pr-MPO induced cell death 
Results obtained from previous experiments had implied a probable involvement of 
lysosomal calcium in Pr-MPO-mediated cell death, evidenced by attenuation of 
lysosomal calcium intake by calcium modulators which also blocked autophagy and 
cell death event. Therefore, the next question awaited to address was whether Pr-
MPO-evoked intracellular calcium response, especially lysosomal calcium intake was 
an upstream signals in regulation of downstream cell death event. In an attempt to 
block Pr-MPO-exerted cytotoxicity, cells were pre-treated with different doses of Bal-
A1 ranging from 0.25 to 1µM. During short-term imaging acquisition (5-10min), high 
concentration of Bal-A1 (1µM) did no harm to cells, however, it resulted in massive 
cell death during long-term incubation due to the cytotoxicity of Bal-A1 per se. 
Therefore, among these tested doses, only 0.25µΜ Bal-A1 was able to render a 
meaningful result without triggering noticeable cell death. As illustrated in Figure 28, 
Bal-A1-primed cells exhibited a greater tolerance to Pr-MPO-exerted cytotoxicity 
compared to cells treated with Pr-MPO alone. A pronounced percentage of cell 
viability loss (~35%) was restored by pre-incubating cells with Bal-A1, indicating a 
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causative role of lysosomal calcium influx in regulation of downstream cell death 
event.  
The involvement of lysosomes as the major site of action in Pr-MPO-induced cell 
death was further corroborated by detection of increased cathepsin L activity in cell 
lysates following drug treatment. Cells were harvested and subjected to cathespin L 
activity measurement after incubation with Pr-MPO for different durations (3, 6, and 
9h). Positive control provided by the commercial kit was used for validating the 
experimental procedure. As shown in Figure 29, a robust increase of cathepsin L 
activity was detected from 3h after treatment of Pr-MPO. Cathespsin L activity 
sustainably increased and reached a peak after prolonged incubation with Pr-MPO, 
which was comparable to what was observed with positive control. At the later 
incubation point, cathespin L activity had dropped back to its resting status due to the 
onset of cell death. This preliminary finding of cathespin L activity provided further 
evidence of involvement of lysosomes in cell death induced by Pr-MPO. Increased 
cytosolic calcium has previously been reported to elicit lysosomal membrane 
permeabilization through activation of lysosomal proteolytic enzymes (Yamashima, 
Saido et al. 1996, Yamashima, Tonchev et al. 2003). Although we have no direct 
evidence of lysosomal calcium in regulation of lysosomal membrane permeabilization 
at this stage of our study, it is very plausible to speculate that accumulation of calcium 
evoked by Pr-MPO resulted in proteolytic enzymes release from lysosome into 






Figure 28.  Bafilomycin A1 successfully restores Pr-MPO-exerted cell viability 
loss. Cells were incubated with 5mM Pr-MPO for 18h with or without pre-treatment 
of 0.25µM Bafilomycin A1. Cell viability was determined by crystal violet assay and 
expressed as % of untreated control. Data are shown as means ± s.e.m of three 













Figure 29. Robust cathepsin L activity is detected in cell lysates following Pr-
MPO treatment. Cells seeded on 96-well plate were incubated with 5µM Pr-MPO 
for 3, 6 and 9h. Treated cells were assayed for cathespin L activity as described in 






In this thesis, I report the findings of my research project aimed at understanding the 
molecular mechanisms of the anti-cancer activity of a novel rare earth metal conjugate, 
Pr-MPO.  The results provide an interesting account of a hitherto undefined 
mechanism of action implicating acidic intracellular organelles, i.e, lysosomes, and 
calcium oscillations, resulting in non-apoptotic execution of human cancer cell lines 
as well as significantly inhibiting tumor growth in a murine xenograft model.  This 
lanthanide conjugate elicited potent ability to inhibit tumor colony formation at 
relatively low micro molar concentrations, even in cells in which the classical 
apoptotic signaling had been rendered ineffective. Interestingly, calcium chelators as 
well as inhibitors of lysosomal acidification not only prevented the accumulation of 
calcium in the lysosomes but also rescued cells from the lethal effect of the compound.  
These results provide a novel strategy against cancer cells eliciting an important 
acquired hallmark of resistance to apoptosis, as most chemotherapeutic agents used in 
the clinic target cancer cells by engaging the apoptotic pathway.    
 
1. Novel lanthanide conjugate executes cancer cells via a non-classical death 
phenotype 
Lanthanides are rare earth metals and have found applications in various industrial 
settings, such as in optic and electronic as well as metallurgy industry. Their 
biochemical properties have also rendered them as useful imaging tools in the 
diagnostic industry (Zhang, Li et al. 2011).  While there is some evidence of their 
biological activity in animal systems, a road understanding of how these interesting 
positively charged trivalent metals elicit their biological activity (Fricker 2006, 
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Naccache, Rodriguez et al. 2012).  Many a studies have reported results with two such 
compounds, gadolinium and lanthanum, such as in neuronal signaling and animal 
toxicity studies (Kumamoto and Murata 1996, Roland, Naziruddin et al. 1999). Our 
laboratory has been interested in one of the lanthanides, praesodynium (Pr3+), and a 
conjugate of this metal Pr-MPO was synthesized and characterized and in an earlier 
study shown to be a mild activator of the nuclear receptor PPAR-γ.  Though, the 
compound elicited activity against a neuroblastoma cell lines (unpublished data), the 
exact mechanism and mode of cell death remained unclear.  Therefore, a major focus 
of this work was to decipher the signaling networks and underlying molecular 
mechanism(s) triggered by this small molecule in vitro and in a xenograft murine 
model.  The first observation that intrigued my curiosity and stimulated my interest in 
pursuing this work was the ability of this compound to target human cancer cells lines 
that had been rendered resistant to apoptotic execution.  This is important due to the 
fact that most chemotherapeutic agents employed for the treatment of various cancers 
elicit their anti-cancer activity by engaging the classical apoptotic pathway, receptor 
or mitochondria-mediated. Tumor cells evade execution by either suppressing the 
expression of pro-apoptotic proteins such as Bax, p53, caspase 8/3 or by upregulating 
the expression of apoptosis inhibitor proteins, such as Bcl-2, Bcl-xL, Mcl-1, XIAP 
and IAP.  The ability of Pr-MPO to target cancer cells, irrespective of the defect in 
apoptotic signaling suggested a mode of cell death that could bypass drug resistance 
mechanisms. Further inquiry into the death execution phenotype confirmed that 
caspases, the central orchestrators of apoptosis, were not induced in cells upon drug 
treatment, and that the pan-caspase inhibitor zVAD-fmk failed to rescue cell viability 
and the inhibition in tumor colony formation (Kroemer and Martin 2005).  
Interestingly, biochemical analysis revealed the ability of the compound to activate 
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autophagy in cells, which suggested that autophagy might account for the anti-cancer 
activity (Jin and White 2007, Mathew, Karantza-Wadsworth et al. 2007).  Autophagy 
has been associated with the classical survival phenotype in nutrient deprived states, 
however, there is accumulating evidence that activation of autophagy not only occurs 
in tandem with other cell death pathways, such as apoptosis, but that autophagy itself 
could serve as a cell death mechanism. This is usually confirmed by the ability of the 
PI3K inhibitor, 3-Methyladenine (3-MA), or the gene knockdown of essential 
autophagy associated genes (Atgs), to rescue cells form the death inducing activity of 
a stimulus (Alers, Loffler et al. 2012).  Notably, lysates obtained from drug treated 
cells showed a robust inhibition of mTOR activity, assayed by western blot analysis 
of downstream substrates, followed by induction of autophagy hallmarks; however, 
neither pharmacological nor genetic inhibitor of autophagy were able to restore cell 
viability. In addition, as discussed in detail under the Results section, using a variety 
of tools, the results seem to indicate that autophagic flux was incomplete and that, 
despite the features consistent with autophagy, the process was inefficient. 
Furthermore, results did not seem to implicate RIP-1 kinase dependent necroptosis as 
a probable death phenotype.  These results suggested that Pr-MPO induced a death 
phenotype distinct from apoptosis and autophagy, however with hallmarks that appear 
to engage one or the other as evidenced upon electron microscopy of treated cells. 
 
2. Involvement of calcium in Pr-MPO induced anti-cancer activity 
The inability of apoptosis and autophagy inhibitors to rescue cells from Pr-MPO 
induced toxicity, suggested a pathway that might involve a ‘necrosis-like’ phenotype, 
but perhaps distinct from the classical TNF-alpha mediated necroptosis activation. 
Over the past couple of decades, while apoptosis has been well characterized both at 
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genetic and biochemical levels, necrosis has mostly been considered as a passive form 
of death (Zong and Thompson 2006). However, recent evidence provides strong 
support to the contrary by demonstrating that necrotic cell death is regulated and also 
plays a vital role in organismal homeostasis. Furthermore, newer descriptions of 
various necrosis like phenotypes have emerged, such as autosis (Liu and Levine 2014), 
necroptosis (Degterev, Huang et al. 2005), pyroptosis (Cookson and Brennan 2001), 
oncosis (Majno and Joris 1995) and lysosomal cell death (Guicciardi, Leist et al. 2004) 
to describe non-apoptotic cell death that displays a controlled mode of cellular demise. 
Moreover, important mediators involved in necrotic cell death initiation, propagation 
and execution have been characterized and documented such as TNF-induced necrotic 
cell death in L929 cells in the presence of zVAD-fmk has uncovered serine/threonine 
kinase RIP1 (receptor-interacting protein kinase), which contains a death domain and 
acts as a central initiator of necroptosis (Vercammen, Beyaert et al. 1998). Similarly, 
calcium and reactive oxygen species (ROS) trigger necrotic cell death, directly or 
indirectly, by inducing damage to macromolecules such as proteins, DNA and lipids.  
The allosteric inhibitor, Necrostain-1, is widely used to examine the contribution of 
RIP1 Kinase in necroptotic cell death (Degterev, Hitomi et al. 2008). Application of 
necrostatin-1 or genetic silencing of RIP1 kinase failed to block Pr-MPO induced cell 
death, which essentially ruled out the involvement of RIP1K in the death inducing 
activity. Moreover, Pr-MPO at concentrations capable of substantial cytotoxicity 
(5µM) didn’t engender any detectable cellular ROS, and ROS inhibitors targeting 
different ROS species had no effect on drug-induced anti-cancer activity.  
It is rather intriguing to note that chelating calcium virtually completely abrogated the 
anti-cancer activity of this small molecule.  Calcium signaling has been associated 
with a variety of cellular processes, ranging from cell survival, proliferation to 
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apoptosis and necrosis.  The cytosolic concentration of calcium is kept in check by 
large intracellular stores of calcium, the ER and mitochondria. Stress stimuli that 
compromise the integrity of the ER or mitochondria result in the accumulation of 
cytosolic calcium with wide-ranging effects, depending upon the concentration.  The 
ionic transport mechanisms regulating the ER levels of calcium are well described and 
involve specific channel proteins that affect uptake or release of calcium in response 
to specific signals.  It has also been demonstrated that the ER and mitochondria are 
involved in an intricate crosstalk to ascertain low micro molar levels of cytosolic 
calcium (Romagnoli, Aguiari et al. 2007). The finding that calcium chelation rescued 
cells from the effects of Pr-MPO suggested two possibilities: (i) that the effect was 
solely a function of increased uptake of calcium triggered by Pr-MPO, and (ii) where 
the increase in uptake of calcium might be secondary to activation of intracellular 
stores, such as the ER, involving channels referred to as SOCE (store operated 
channels). SOCE channels open up in response to a massive leak out of calcium from 
intracellular stores in an attempt to restore organelle calcium levels (Palty, Raveh et al. 
2012). Using the classical calcium sensors it was established that Pr-MPO elicited a 
robust increase in intracellular calcium; however this increase in cytosolic calcium did 
not seem to be ER mediated as inhibitors of specific calcium channels in the ER did 
not have a significant effect on Pr-MPO-induced increase in intracellular calcium, 
detected qualitatively by flow cytometry.  Furthermore, results showed a distinctly 
different kinetic and pattern of calcium accumulation from what was obtained with 
thapsigargin, an agent that rapidly induced emptying of ER calcium.  It is noteworthy 
that calcium chelators also blocked the ability of Pr-MPO to trigger autophagy despite 
the fact that autophagy inhibitors did not rescue cells from the lethal effect of the 
compound. These results pointed to a possible intracellular compartment involved not 
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only in the regulation of cellular calcium, but also somehow involved in the 
autophagy pathway.  Indeed, recent evidence does provide testimony to link calcium 
to autophagy; however, as autophagy appeared as a bystander effect in the anti-cancer 
activity of Pr-MPO, the effect of chelating calcium on autophagy was not explored 
further in this study.   
 
3. Real time confocal imaging revealed a distinct pattern of calcium 
accumulation in acidic vacuoles  
Intrigued by the findings linking calcium signaling to the cytotoxic activity of Pr-
MPO, real time confocal imaging was utilized for visualization of intracellular 
calcium. A remarkable punctate pattern of calcium accumulation was observed within 
minutes of exposure to Pr-MPO. This pattern was again distinctly different from 
thapsigargin, thus ruling out ER as a target.  Interestingly, a careful look at the real 
time videos revealed that despite a uniform increase in cytosolic calcium, Fluo4-AM 
fluorescence in these aggregate-like calcium puncta was persistently elevated in a 
temporal manner, which was in proportion to the amount of [Ca2+] in the small 
vesicular bodies. Notably, the presence of various calcium modulators not only 
abrogated Pr-MPO-induced cytotoxicity but also attenuated the increase in 
intracellular calcium accumulation, thereby corroborating that drug-induced cell death 
closely correlated with intracellular calcium fluxes.  
As alluded to above, calcium oscillations from extracellular sources and/or 
intracellular stores are tightly regulated by a host of calcium exchanger and active 
transport pumps (Clapham 2007).  These are best characterized and well-studied in 
the ER, one of the major calcium repertoires. In addition, evidence also indicates that 
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mitochondria serve as sensors and regulators of calcium signaling and can transiently 
sequester calcium. Furthermore, pertinent to the findings reported in this work, recent 
reports provide support for the existence of a high concentration calcium pool 
localized to a variety of acidic compartments in prokaryotic and eukaryotic cells 
(Pozzan, Rizzuto et al. 1994). Dysfunction of acidic calcium stores and deregulation 
of calcium signaling have been associated with a number of human pathologies (Styrt, 
Pollack et al. 1988, Shen, Wang et al. 2012).  
The most important intracellular acidic compartment is the lysosomes.  Having ruled 
out the ER and mitochondria as the site of calcium puncta formation, cell-impermeant 
dextran-conjugated fluorescent probes, Calcium Green-1 dextran and Texas Red 
dextran and time-lapsed confocal microscopy were used to decipher whether the 
calcium puncta were localized to the lysosomes. Indeed, emission fluorescence 
intensity from calcium green-1 was reinforced over the time course of drug treatment, 
indicating that calcium influx or elevation took place inside the lysosomes. It is 
noteworthy that by lowering intracellular calcium with Bapta-AM, an inhibitory effect 
was observed on cytosolic and lysosomal calcium, similar to that of the other two 
extracellular calcium modulators (EGTA and CoCl2). However, only a partial rescue 
in Pr-MPO-induced cell death was observed with Bapta-AM. This might be due to the 
inefficiency of Bapta-AM in chelating calcium fluxed from extracellular environment, 
the remnant of which was sufficient enough to augment the downstream cell death 
signaling.  
 
4. Lysosomal calcium accumulation occurs in a pH dependent manner 
There is strong experimental evidence that a probable mechanism by which Pr-MPO 
induces calcium signaling is by first activating calcium influx from the extracellular 
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pool, followed by elevation in cytosolic and lysosomal calcium, which serves as a 
possible trigger for death execution. Interestingly, calcium uptake into intracellular 
acidic compartments, in particular the lysosomes, is primarily accomplished by 
calcium pumps or exchangers (enlisted in the Introduction section).  As the intra-
organelle calcium concentration is an order of magnitude higher than cytosolic 
calcium, the influx of calcium into various membrane bounded organelles is actively 
accomplished via the calcium ATPase pumps (Carafoli and Brini 2000). In 
invertebrate eukaryotes such as trypanosomes, yeast, and Dictyostelium, calcium 
ATPase pumps of similar nature have been reported in the acidocalcisome vacuoles, 
Gogi apparatus and lysosome-related organelles (Cunningham and Fink 1994, 
Moniakis, Coukell et al. 1999). As the presence of such active transport pumps have 
not been reported in the acidic compartments of mammalian cells, calcium ATPase 
activity is unlikely to be the primary candidate responsible for lysosomal calcium 
influx induced upon exposure to Pr-MPO.  
 
Interestingly, an earlier report from the Swanson group had elegantly demonstrated 
that the large proton gradient across the membrane of acidic vacuoles was responsible 
for driving the uptake of calcium (Christensen, Myers et al. 2002).  In this regard, pH-
dependent regulation of lysosomal calcium has been reported in mouse macrophages 
despite the fact that calcium-hydrogen exchangers have not been identified in 
mammalian genomes. Interestingly, inhibition of the H+-V-ATPase with Bal-A1 
virtually completely inhibited Pr-MPO-evoked lysosomal calcium puncta formation. 
This is due to the fact that Bal-A1 dissipated H+ gradient promptly by paralyzing V-
ATPase activity, which lead to a consequential disruption of calcium flow transported 
from cytosol into lysosomal lumen. This result is in agreement with the notion that 
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lysosomal calcium uptake is dependent upon a proton electrochemical gradient that 
can be readily utilized to transport calcium ion uphill into vesicle lumen of lysosomes. 
One  
needs to also entertain the possibility that the calcium-hydrogen exchange activity 
may not be attained by a single protein, but a synergetic effect of sodium hydrogen 
exchangers (NHEs) and sodium calcium exchangers (Patel and Docampo 2010). 
Of note, measurement of intra-lysosomal pH (pHly) using specific fluorescent probes 
indicated that Pr-MPO elicited a small increase in lysosomal pH concomitant with a 
significant decrease in cytosolic pH (pHi). These results indicate that under the 
conditions where lysosomal pH is moderately increased by Pr-MPO, a correspondent 
drop in cytosolic pH is expected.  Furthermore, with an elevated [H+] in cytosol, the 
likelihood of a significant reduction in lysosomal [H+] is rather low. Therefore, Pr-
MPO-evoked  pHly increase may not be a secondary to pHi changes, but could be a 
function of [Ca2+]ly uptake via Na+/H+ and Na+/Ca2+ exchangers located on lysosomal 
membranes.  
Does lysosomal calcium and pH response account for the anti-cancer activity of Pr-
MPO?  Indeed, results obtained with the H+-V ATPase inhibitor, Baf-A1, indicates 
that blocking lysosomal acidification resulted in a significant rescue of cells ability to 
form colonies upon drug exposure.  Furthermore, measurement of cathepsin activity 
in the lysates of drug-treated cells provide further evidence that the lysosomal 
machinery plays a critical role in cell death induced by Pr-MPO; cathepsins are 
lysosomal enzymes that are released upon a compromise in the permeability of the 
lysosomes (Boya and Kroemer 2008, Lin, Epstein et al. 2010). It is plausible that 
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accumulation of calcium triggered by Pr-MPO results in the release of proteolytic 





In light of the results indicating the involvement of calcium in the anti-cancer activity 
of the small molecule lanthanide conjugate, it would only be appropriate to mention 
that there are some earlier references to a relationship between calcium loading in 
organs as well as blocking calcium channel activity with lanthanides such as 
gadolinium and others. Also in studies on neuronal cells, the effect has been attributed 
to blocking of calcium channels and inhibiting calcium-mediated signaling, for 
instance in GABBA and glutumate receptor triggered responses.  Notably, this effect 
on calcium-channel activity has been proposed to be a function of similar ionic radii 
of trivalent lanthanides and calcium channels, however in separate experiments effects 
on ATP driven channels have also been observed.  Despite these earlier indications, 
there has not been a comprehensive study outlining the biological effects and 
mechanisms of calcium-mediated responses elicited by this group of rare earth metals.  
In particular, results described in this thesis point to a novel, hitherto undefined, 
mechanism of activation of calcium uptake by Pr3+ conjugate in cancer cells that 
results in a rapid accumulation of lysosomal calcium in a pH dependent manner.  
These results suggest a novel lysosomotropic activity of this small lanthanide 
conjugate that elicits potent anti-cancer activity in vitro and in vivo. Whilst this work 
contributes significantly to our understanding of the molecular mechanisms 
underlying the anti-cancer activity of Pr-MPO, it also provides an avenue for future 
work into the identification and characterization of specific calcium transport 
mechanisms at the lysosomal membranes. Most importantly, the ability of this 
compound to target cancer cells harboring an apoptosis resistant phenotype bodes well 
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for the future design and development of similar agents against cancers that are 
refractory to conventional therapies.   
 
 
Figure 30. Schematic diagram representing the signalling network evoked by Pr-
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2. Determination of Pr-MPO solubility 
The compound solubility, permeability and other physical properties were conducted 
by The Drug Development Unit, NUS with the generous assistance of A/Prof. Brian 
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